Dengvaxia

1 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX I  
 

SUMMARY OF PRODUCT CHARACTERISTICS  



 2 

This medicinal product is subject to additional monitoring. This will allow quick identification of 
new safety information. Healthcare professionals are asked to report any suspected adverse reactions. 
See section 4.8 for how to report adverse reactions. 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Dengvaxia, powder and solvent for suspension for injection in pre-filled syringe 
dengue tetravalent vaccine (live, attenuated) 
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
After reconstitution, one dose (0.5 mL) contains: 
 
Chimeric yellow fever dengue virus serotype 1 (live, attenuated)* ........... 4.5 - 6.0 log10 CCID50/dose** 
Chimeric yellow fever dengue virus serotype 2 (live, attenuated)* ........... 4.5 - 6.0 log10 CCID50/dose** 
Chimeric yellow fever dengue virus serotype 3 (live, attenuated)* ........... 4.5 - 6.0 log10 CCID50/dose** 
Chimeric yellow fever dengue virus serotype 4 (live, attenuated)* ........... 4.5 - 6.0 log10 CCID50/dose** 
 
*Produced in Vero cells by recombinant DNA technology. This product contains genetically modified 
organisms (GMOs). 
**CCID50: 50% Cell Culture Infectious Dose. 
 
Excipients with known effect: (see Section 4.4) 
Phenylalanine………………41 micrograms 
Sorbitol…………….……….9.38 milligrams 
 
For a full list of excipients, see section 6.1. 
 
 
3. PHARMACEUTICAL FORM 
 
Powder and solvent for suspension for injection 
 
Prior to reconstitution, the vaccine is a white, homogenous, freeze-dried powder with possible 
retraction at the base (ring-shaped cake possible). 
 
The solvent is a clear and colourless solution. 
 
 
4. CLINICAL PARTICULARS 
 
4.1 Therapeutic indications  
 
Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 
and 4 in individuals 9 to 45 years of age with prior dengue virus infection and living in endemic areas 
(see sections 4.2, 4.4 and 4.8). 
 
The use of Dengvaxia should be in accordance with official recommendations. 
 
4.2 Posology and method of administration  



 3 

 
Posology 
 
Children and adults 9 to 45 years of age 
 
The vaccination schedule consists of 3 injections of one reconstituted dose (0.5 mL) to be 
administered at 6-month intervals. 
 
Other paediatric population 
 
Dengvaxia should not be used in children less than 9 years of age (see sections 4.8).  
In vaccinees 2 to 8 years of age with no previous dengue infection, long-term safety follow-up data 
showed an increased risk of dengue disease requiring hospitalisation including clinically severe 
dengue. Available data are not sufficient to confirm the safety and efficacy in individuals previously 
infected by any dengue virus and younger than 9 years. 
 
Method of administration 
 
Previous dengue infection has to be assessed before vaccination by laboratory confirmed history of 
dengue or through an appropriately validated serological test (see section 4.4). 
 
Immunisation should be carried out by subcutaneous (SC) injection preferably in the upper arm in the 
region of deltoid. 
 
Do not administer by intravascular injection. 
 
For instructions on reconstitution of Dengvaxia before administration, see section 6.6. 
 
4.3 Contraindications 
 
• Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or after 

prior administration of Dengvaxia or a vaccine containing the same components. 
 
• Individuals with congenital or acquired cell-mediated immune deficiency, including 

immunosuppressive therapies such as chemotherapy or high doses of systemic corticosteroids 
(e.g. 20mg or 2mg/kg of prednisone for 2 weeks or more) within 4 weeks prior to vaccination. 

 
• Individuals with symptomatic HIV infection or with asymptomatic HIV infection when 

accompanied by evidence of impaired immune function. 
 
• Pregnant women (see section 4.6). 
 
• Breast-feeding women (see section 4.6). 
 
4.4 Special warnings and precautions for use 
 
Protection 
 
A protective immune response with Dengvaxia may not be elicited in all vaccinees. It is recommended 
to continue personal protection measures against mosquito bites after vaccination. 
 
Special patient groups 
 
Individuals who have not been previously infected by dengue virus or for whom this information is 
unknown 
 



 4 

Individuals who have not been previously infected by dengue virus or for whom this information is 
unknown should not be vaccinated because an increased risk of hospitalisation for dengue and 
clinically severe dengue (predominantly grade 1 or 2 Dengue Hemorrhagic Fever) has been observed 
in these individuals during the long-term follow up of clinical trials (see Section 4.8). 
 
In the absence of documented prior dengue virus infection, previous infection has to be confirmed by 
serotesting before vaccination. To avoid vaccination of false positives, only test methods with 
adequate performance in terms of specificity and cross-reactivity based on the local disease 
epidemiology should be used.  
 
Travellers 
 
There are no safety, immunogenicity or efficacy data to support vaccination of individuals living in 
non-endemic areas and travelling to endemic areas, therefore vaccination of these individuals is not 
recommended.  
 
Outbreaks 
 
Dengvaxia should not be used in the context of dengue outbreak in non-endemic regions. 
 
Others 
 
Administration of Dengvaxia must be postponed in individuals suffering from moderate to severe 
febrile or acute disease. 
 
Vaccination should be preceded by a review of the individual's medical history (in particular, previous 
vaccinations and possible adverse reactions which occurred after vaccination). 
 
Appropriate medical treatment and supervision must always be readily available in the event of an 
anaphylactic reaction following administration of the vaccine. 
 
Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to 
injection with a needle. Procedures should be in place to prevent injury from falling and to manage 
syncopal reactions. 
 
The tip caps of the prefilled syringes contain a natural rubber latex derivative, which may cause 
allergic reactions in latex sensitive individuals. 
 
Women of childbearing potential have to use effective contraception during at least one month after 
each dose (see section 4.6). 
 
Dengvaxia must not be administered by intravascular injection under any circumstances. 
 
Dengvaxia contains phenylalanine, sodium and sorbitol 
 
Dengvaxia contains 41 micrograms of phenylalanine in each 0.5 ml dose. Phenylalanine may be 
harmful for people with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds 
up because the body cannot remove it properly. 
 
Dengvaxia contains less than 1mmol of sodium (23 mg) per 0.5 ml dose, that is to say essentially 
“sodium-free”. 
 
Dengvaxia contains 9.38 milligrams of sorbitol in each 0.5 ml dose. 
 
Traceability 
 



 5 

In order to improve the traceability of biological medicinal products, the name and the batch number 
of the administered product should be clearly recorded. 
 
4.5 Interaction with other medicinal products and other forms of interaction  
 
For patients receiving treatment with immunoglobulins or blood products containing 
immunoglobulins, such as blood or plasma, it is recommended to wait for at least 6 weeks, and 
preferably for 3 months, following the end of treatment before administering Dengvaxia, in order to 
avoid neutralization of the attenuated viruses contained in the vaccine. 
 
Dengvaxia should not be administered to subjects receiving immunosuppressive therapies such as 
chemotherapy or high doses of systemic corticosteroids within 4 weeks prior to vaccination (see 
section 4.3). 
 
As there are no data on co-administration of Dengvaxia vaccine with other vaccines for the population 
from 9 years and above, the concomitant use of Dengvaxia with other vaccines is not recommended. 
 
4.6 Fertility, pregnancy and lactation  
 
Pregnancy 
 
Animal studies did not indicate any direct or indirect harmful effects with respect to reproductive 
toxicity (see section 5.3). 
 
There is limited amount of data from the use of Dengvaxia in pregnant women. These data are not 
sufficient to conclude on the absence of potential effects of Dengvaxia on pregnancy, embryo-foetal 
development, parturition and post-natal development. 
 
Dengvaxia is a live attenuated vaccine, therefore Dengvaxia is contraindicated during pregnancy (see 
section 4.3). 
  
Women of childbearing potential have to use effective contraception during at least one month after 
each dose. 
 
Breast-feeding 
 
Animal studies did not indicate any direct or indirect harmful effects with respect to lactation. 
There is very limited experience on dengue virus excretion via breast milk. 
Also, considering that Dengvaxia is a live attenuated vaccine and that there is very limited experience 
from post marketing data with Dengvaxia in lactating women, the vaccine is contraindicated during 
lactation (see section 4.3). 
 
Fertility 
 
No specific studies have been performed on fertility. 
Animal studies did not indicate any harmful effects with respect to female fertility (see section 5.3). 
 
4.7 Effects on ability to drive and use machines  
 
Dengvaxia has minor influence on the ability to drive and use machines. 
 
4.8 Undesirable effects  
 
a.  Summary of the safety profile 
 



 6 

In subjects 9 to 45 years of age, the most frequently reported reactions whatever the dengue serostatus 
prior to vaccination, were headache (54%), injection site pain (49%), malaise (44%), myalgia (43%), 
asthenia (34%), and fever (16%). 
 
Adverse reactions occurred within 3 days following vaccination except fever which appears within 14 
days after the injection. The adverse reactions were usually mild to moderate in severity and of short 
duration (0 to 3 days). 
 
Systemic adverse reactions tended to be less frequent after the second and third injections of 
Dengvaxia as compared to the first injection. 
 
Allergic including anaphylactic reactions have been reported very rarely. 
 
Overall, the same adverse reactions but at lower frequencies were observed in dengue seropositive 
subjects. 
b.  Tabulated list of adverse reactions  
 
Adverse reactions are listed according to the following frequency categories:  
Very common: ≥ 1/10 
Common: ≥ 1/100 to < 1/10 
Uncommon: ≥ 1/1000 to < 1/100 
Rare: ≥ 1/10 000 to < 1/1000 
Very rare: (<1/10 000) 
 
Adverse reactions collected within 28 days after any injection during clinical studies from 9 to 45 
years of age, on a reactogenicity subset of 1306 adults and 3067 children, and adverse reactions 
observed during commercial use are presented in Table 1 for children 9 to 17 years old and in Table 2 
for adults 18 to 45 years old.  
 
Table 1: Adverse reactions from Clinical Studies and reported during commercial use in 
children (9 to 17 years old) 
 



 7 

System Organ Class  Frequency  Adverse Events  
Infections and infestations  Rare Upper respiratory tract infection 

Immune system disorders Very rare Allergic including anaphylactic reactions* 

Nervous system disorders 
 

Very common Headache 
Rare  Dizziness 

Respiratory, thoracic and 
mediastinal disorders 

Rare  Oropharyngeal pain 
Cough 
Rhinorrhoea 

Gastrointestinal disorders Rare  Nausea 

Skin and subcutaneous 
tissue disorders 

Uncommon Urticaria 
Rare  Rash 

Musculoskeletal and 
connective tissue disorders 

Very common Myalgia 
Rare  Neck pain 

General disorders and 
administration site 
conditions 

Very common Injection site pain 
Malaise 
Asthenia 
Fever 

Common Injection site reactions (erythema, swelling) 
Uncommon Injection site reactions (hematoma, pruritus) 

Injection site induration 
* Adverse reactions from spontaneous reporting. 
 



 8 

Table 2: Adverse reactions from Clinical Studies and reported during commercial use in adults 
(18 to 45 years old) 
 

System Organ Class  Frequency  Adverse Events  
Infections and infestations  Uncommon Upper respiratory tract infection 

Nasopharyngitis 
Blood and lymphatic 
tissue disorders 

Uncommon Lymphadenopathy 

Immune system disorders Very rare Allergic including anaphylactic reactions* 

Nervous system disorders 
 

Very common Headache 
Uncommon Dizziness 

 
Respiratory, thoracic and 
mediastinal disorders 

Uncommon Oropharyngeal pain 
Cough 
 

Gastrointestinal disorders Uncommon Nausea 
Dry mouth 

Skin and subcutaneous 
tissue disorders 

Uncommon Rash 
Rash generalised 

Musculoskeletal and 
connective tissue disorders 

Very common Myalgia 
Uncommon Neck pain 

Arthralgia 
General disorders and 
administration site 
conditions 

Very common Injection site pain 
Malaise 
Asthenia 

Common Fever 
Injection site reactions (erythema, hematoma, 
swelling, pruritus) 

Uncommon Injection site induration 
Injection site warmth 
Chills 
Fatigue 

* Adverse reactions from spontaneous reporting. 
 
c.  Hospitalised and/or clinically severe dengue fever in long-term safety follow-up data 
 
In an exploratory analysis of the long-term follow up from the first injection in three efficacy studies, 
an increased risk of hospitalisation for dengue including clinically severe dengue (predominantly 
Dengue Haemorrhagic Fever grade 1 or 2 [WHO 1997]) has been observed in vaccinees with no 
previous dengue infection. Over a period of 6 years, in subjects with no previous dengue infection, the 
risk of severe dengue is increased by 2.41 fold (95% CI: 0.50; 11.75) in subjects 9 to 16 years of age 
vaccinated with Dengvaxia as compared to non-vaccinated subjects in the same age group. In subjects 
9 years of age or older, it was estimated that during a 6 year follow-up about 5 additional hospitalized 
dengue cases or 3 additional severe dengue cases per 1000 vaccinees with no previous dengue 
infection could occur following vaccination. Estimates from the long-term analysis suggest the onset 
of increased risk was mainly during the 3rd year following the first injection.  
This increased risk was not observed in individuals who have been previously infected by dengue 
virus, where it was estimated that 16 hospitalized dengue cases or 4 severe dengue cases could be 
prevented per 1000 vaccinees with previous dengue infection during 6 years of follow up from the first 
injection. 
 
The estimations described above for a 6 year period are derived from data obtained in the pivotal 
clinical trials in countries with a particular dengue seroprevalence and epidemiological context. These 
figures may not be extrapolated to other regions with different seroprevalence and epidemiological 
situations. 



 9 

 
d.  Paediatric population 
 
Paediatric data in subjects 9 to 17 years of age 
 
In paediatric population, fever has been observed with a higher frequency (very common) than in 
adults (common). 
 
Urticaria (uncommon) was only reported in subjects 9 to 17 years of age (none in adults). 
 
Paediatric data in subjects below 9 years of age, i.e., outside the age indication 
 
The reactogenicity subset in subjects below 9 years of age includes 2960 subjects as follows: 1287 
subjects below 2 years of age, 905 subjects between 2 and 5 years of age and 768 subjects between 6 
and 8 years of age. 
 
In subjects 2 to 8 years of age, as compared to subjects above 9 years of age, injection site erythema 
and swelling were more frequently reported (frequency: very common), and additional adverse events 
were reported (frequency: uncommon): injection site haemorrhage, decreased appetite and vomiting. 
 
In subjects 2 to 8 years of age, with no previous dengue infection, long-term safety follow-up data 
showed an increased risk of dengue disease requiring hospitalisation including clinically severe 
dengue in vaccinated subjects as compared to non-vaccinated subjects. 
 
In subjects below 2 years of age, the most frequently reported adverse reactions following any 
injection of Dengvaxia were fever, irritability, appetite lost, abnormal crying and injection site 
tenderness. 
 
Reporting of suspected adverse reactions 
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 
professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V. 
 
4.9 Overdose  
 
No cases of overdose have been reported. 
 
 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1  Pharmacodynamic properties  
 
Pharmacotherapeutic group: Vaccines, Viral vaccines, ATC code: J07BX/ Not Yet assigned 
 
1. Mechanism of action 
 
Dengvaxia contains live attenuated viruses. Following administration, the viruses replicate locally and 
elicit neutralizing antibodies and cell-mediated immune responses against the four dengue virus 
serotypes (see detailed data below, subsection 3). 
 
2. Clinical efficacy 
 
The clinical efficacy of Dengvaxia was assessed in 3 studies: one supportive Phase IIb efficacy study 
(CYD23) in Thailand, and 2 pivotal large-scale Phase III efficacy studies, CYD14 in Asia (Indonesia, 
Malaysia, the Philippines, Thailand, Vietnam) and CYD15 in Latin America (Brazil, Colombia, 
Honduras, Mexico, Puerto Rico). 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 10 

 
The Control Group in dengue studies was defined as subjects who received at least one injection of 
placebo or comparator vaccine. 
 
In the Phase IIb study, a total of 4002 subjects aged 4 to 11 years were randomised to receive 
Dengvaxia or a control, regardless of previous dengue infection. Efficacy in subjects 9 to 11 years of 
age was assessed in 1554 subjects (1032 in vaccine group and 522 in Control Group). 
 
In the two pivotal Phase III studies (CYD14 and CYD15), a total of approximately 31000 subjects 
aged 2 to 16 years were randomised to receive either Dengvaxia or placebo, regardless of previous 
dengue infection. Efficacy in subjects 9 years of age and older was assessed in 17 230 subjects who 
received Dengvaxia (3316 subjects in CYD14 and 13914 in CYD15) and 8596 subjects who received 
placebo (1656 in CYD14 and 6940 in CYD15). 
 
At the start of the CYD14 and CYD15 trials, dengue seroprevalence for the overall population at the 
trial sites ranged from 52.8%-81.1% in CYD14 (Asia-Pacific) and 55.7%-92.7% in CYD15 (Latin 
America). 
 
The efficacy was assessed during an Active Phase of 25 months, in which surveillance was designed 
to maximize the detection of all symptomatic virologically-confirmed dengue (VCD) cases regardless 
of the severity. The active detection of symptomatic dengue cases started on the day of the first 
injection and lasted until each subject had been followed for at least 13 months after the third 
injection. This phase includes therefore the primary endpoint observation period from 28 days after the 
third injection up to the end of the Active Phase. 
 
For the primary endpoint, the incidence of symptomatic VCD cases occurring during the 12-month 
period from 28 days after the third injection was compared to the Control Group. 
 
Exploratory vaccine efficacy analyses according to dengue serostatus measured by plaque reduction 
neutralization test (PRNT50) at baseline (before the first injection) were performed in the 
immunogenicity subset of 2000 subjects each in CYD14 and CYD15 and 300 subjects in CYD23. Of 
the 2930 subjects 9 to 16 years old in this subset (approximately 80%) who were dengue seropositive 
at baseline, 1974 subjects received the vaccine (901 subjects in CYD14 and 1073 in CYD15) and 956 
subjects received placebo (444 in CYD14 and 512 in CYD15) (see also subsection 3). 
 
 
2.1 Clinical efficacy data for subjects 9 to 16 years of age in endemic areas, any serostatus at 
baseline 
 
The Vaccine Efficacy (VE) results according to the primary endpoint (symptomatic VCD cases 
occurring during the 12-month period starting from 28 days after the third injection) in subjects 9 to 16 



 11 

years of age (any serostatus at baseline) are shown in Table 3 for studies CYD14, CYD15 and 
CYD23. 
 
Table 3: VE against symptomatic VCD cases over the 12-month period starting from 28 days 
after the third injection due to any of the 4 serotypes in subjects 9 to 16 years (any serostatus at 
baseline). 
 

 

CYD14 CYD15 CYD23 Pooled CYD14+CYD15 

Pooled* 
CYD14+CYD15+ 

CYD23 

 Vaccine group 
Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Cases / 
person-
years 

34 / 
3199 

55 / 
1585 

185 / 
12458 

236 / 
6157 

6 / 
1033 

10 / 
514 

219 / 
15657 

291 / 
7742 

225 / 
16690 

301 / 
8256 

VE % 
(95%CI) 

69.4  
(52.2; 80.6) 

61.3  
(52.8; 68.2) 

70.1 
(9.3; 91.1) 

62.8  
(55.7; 68.8) 

63.0 
(56.1; 68.9) 

N: number of subjects per study 
Cases: number of subjects with at least one symptomatic virologically-confirmed dengue episode in the considered period. 
Person-years: sum of time-at-risk (in years) for the subjects during the study period. 
CI: confidence interval. 
*Pooled results of CYD14, 15 and 23 need to be interpreted cautiously because of differences in the Dengue confirmatory 
test and acute febrile illness definition between CYD14/15 and CYD23. 
 
In subjects 9 to 16 years of age, the efficacy of Dengvaxia against symptomatic virologically-
confirmed dengue (VCD) cases due to any of the 4 serotypes was demonstrated in all three studies, 
CYD14, CYD15 and CYD23 (see Table 3). 
 
The Vaccine Efficacy (VE) against symptomatic VCD, severe and hospitalised VCD during the 25-
month period after the first injection, which were secondary objectives, in subjects 9 to 16 years of age 
are shown in Table 4 for any serostatus at baseline for studies CYD14, CYD15 and CYD23. For 
severe VCD cases, two types of endpoints were considered: clinically severe VCD cases and VCD 
cases that met the 1997 WHO criteria for Dengue Haemorrhagic Fever (DHF).  
Vaccine efficacy was demonstrated for these endpoints in CYD14 and CYD15 (see Table 4). 
 
The vaccine efficacy against symptomatic VCD is moderate for serotypes 1 and 2 and higher for 
serotypes 3 and 4 (see Table 4). 
 



 12 

Table 4: VE against symptomatic, Hospitalised or Severe VCD over the 25-month period after 
the first injection in subjects 9 to 16 years of age (any serostatus at baseline) 
 

 
CYD14 CYD15 Pooled 

CYD14+CYD15 
CYD23 

Pooled* 
CYD14+CYD15+ 

CYD23 

VE % 
(95% CI) 

VE % 
(95% CI) 

VE % 
(95% CI) 

VE % 
(95%CI) 

VE % 
(95% CI) 

N=4972 N=20854 N=25826 N = 1554 N = 27380 
Symptomatic VCD 

Any serotype 67.8 
(57.7; 75.6) 

64.7 
(58.7; 69.8) 

65.6 
(60.7; 69.9) 

43.3 
(-18.9; 72.7) 

64.9 
(60.0; 69.2) 

Serotype 1 65.7 
(46.6; 78.2) 

54.8 
(40.2; 65.9) 

58.4 
(47.7; 66.9) 

78.4 
(5.4; 96.4) 

59.2 
(48.9; 67.4) 

Serotype 2 36.8 
(-10.1; 63.3) 

50.2 
(31.8; 63.6) 

47.1 
(31.3; 59.2) 

5.9 
(-178.6; 65.1) 

44.6 
(28.9; 56.9) 

Serotype 3 69.5 
(31.9; 87.0) 

74.2 
(63.9; 81.7) 

73.6 
(64.4; 80.4) 

-1.2 
(-5870.2; 94.7) 

73.0 
(63.7; 79.9) 

Serotype 4 87.9 
(75.5; 94.6) 

80.9 
(70.9; 87.7) 

83.2 
(76.2; 88.2) 

100.0 
(-1873.3; 

100.0) 

83.3 
(76.4; 88.2) 

Hospitalised 
VCD† 

81.6 
(60.7; 92.0) 

80.3 
(64.7; 89.5) 

80.8 
(70.1; 87.7) 

72.5 
(19.0; 91.7) 

79.7 
(69.6; 86.5) 

Clinically severe 
VCD cases† 

90.9 
(58.4; 99.0) 

95.5 
(68.8; 99.9) 

93.2 
(77.3; 98.0) 

49.4 
(-3870.3; 99.4) 

91.3 
(74.9; 97.0) 

DHF meeting 
any WHO 
criteria 

90.9 
(58.4; 99.0) 

95.0 
(64.9; 99.9) 

92.9 
(76.1; 97.9) 

100.0 
(-1871.5; 

100.0) 

93.2 
(77.3; 98.0) 

N: number of subjects per study 
CI: confidence interval. 
VE is calculated using density incidence (cases per 100 person-years at risk) 
* Pooled results of CYD14, 15 and 23 need to be interpreted cautiously because of differences in the Dengue confirmatory 
test and acute febrile illness definition between CYD14/15 and CYD23. 
†The efficacy against hospitalised and severe VCD was not a primary objective and cut-off thresholds to define statistical 
significance were not pre-specified. 
 



 13 

2.2 Clinical efficacy data for subjects 9 to 16 years of age in endemic areas, dengue seropositive at 
baseline 
 
The Vaccine Efficacy (VE) results according to exploratory analysis of symptomatic VCD cases 
occurring during the 12-month period starting from 28 days after the third injection in subjects 9 to 16 
years of age, seropositives at baseline are shown in Table 5 for the immunogenicity subset of studies 
CYD14, CYD15 and CYD23. 
 
Table 5: VE against symptomatic VCD cases over the 12-month period starting from 28 days 
after the third injection due to any of the 4 serotypes in subjects 9 to 16 years (dengue 
seropositive at baseline). 
 

 
CYD14 CYD15 CYD23 Pooled CYD14+CYD15 

Pooled * 
CYD14+CYD15+ 

CYD23 

 Vaccine group 
Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Cases / 
person-
years 

4/471 9/241 7/1002 17/472 0/55 0/19 11/1473 26/713 11/1528 26/732 

VE % 
(95%CI) 

77.2 
(18.3; 94.9) 

80.6 
(50.7; 93.2) NC 

79.4 
(58.4; 89.8) 

79.4 
(58.4; 89.8) 

N: number of subjects per study 
Cases: number of subjects with at least one symptomatic virologically-confirmed dengue episode in the considered period. 
Person-years: sum of time-at-risk (in years) for the subjects during the study period. 
CI: confidence interval. 
NC: Not computed (the absence of cases in vaccine and control group does not permit to calculate VE nor CI) 
*Pooled results of CYD14, 15 and 23 need to be interpreted cautiously because of differences in the Dengue confirmatory 
test and acute febrile illness definition between CYD14/15 and CYD23. 
 
The Vaccine Efficacy (VE) against symptomatic VCD during the 25-month period after the first 
injection, in subjects 9 to 16 years of age dengue seropositives at baseline and for the immunogenicity 
subset for pooled CYD14 + CYD15+CYD23, is estimated at 81.9% (95% CI: 67.2 ; 90.0). 
 
In subjects 9 through 16 years of age dengue seropositive at baseline (immunogenicity subset), one 
clinically severe VCD case and one WHO DHF VCD case was reported during the 25-month period 
after the first injection in the control group in each individual study (CYD14 and CYD15) versus none 
in the vaccine group. Four hospitalized VCD cases in CYD14 and two hospitalized VCD cases in 
CYD15 were reported in the control group versus none in the vaccine group. These data are 
inconclusive due to the low number of cases in the immunogenicity subset. However, the extrapolated 
vaccine efficacy (1- Hazard Ratio), obtained from an exploratory analysis (pooled CYD14 + CYD15 + 
CYD23) over 25-month period after the first injection, is estimated at 89.2% (95% CI: 78.5; 94.6) for 
hospitalized VCD and 95.3% (95% CI: 68.9; 99.3) for severe VCD. 
 
2.3 Clinical efficacy data for subjects 17 to 45 years of age in endemic areas 
 
No clinical efficacy study has been done in subjects from 17 to 45 years from endemic areas. The 
clinical efficacy of the vaccine is based on bridging of immunogenicity data (see below section 3.2). 
 
2.4 Other paediatric data from efficacy studies in subjects 2 through 8 years of age, i.e., outside the 
age indication 
 
Efficacy in subjects 2 to 8 years of age was assessed in 2443 subjects (1634 in vaccine group and 809 
in control group) in phase IIb study and in 5300 subjects (3532 subjects in vaccine group and 1768 in 
control group) in the pivotal Phase III study (CYD14). Vaccine efficacy against symptomatic VCD 
cases over the 12-month  period starting from 28 days after the third injection due to any of the 4 
serotypes was 40.5% (95% CI: 22.7; 54.2) (pooled CYD14+CYD23). Vaccine Efficacy against 



 14 

symptomatic, severe and hospitalized VCD during the 25-month period after the first injection due to 
any serotype (pooled CYD14+CYD23), was respectively 42.2% (95% CI: 30.6; 51.8), 45.1% (95% 
CI: 29.3; 76.7),  47.6% (95% CI: 23.7; 64.0).  
 
2.5 Long-term protection 
 
During a period of 6 years after the first injection, in subjects 9 years of age and above with previous 
dengue infection, the extrapolated vaccine efficacy (1-Hazard Ratio)*100 (obtained from an 
exploratory analysis) is estimated at 80 (95% CI: 69; 87) for hospitalized VCD and 84 (95% CI: 61; 
94) for severe VCD. 
 
3. Immunogenicity 
 
During clinical development, immunogenicity data were collected in a total of approximately 
5700 subjects 9 months to 60 years of age that received at least one injection of the vaccine. 
 
Among these 5700 subjects, a total of 3104 subjects 9 to 45 years of age from endemic areas received 
at least one injection of Dengvaxia. Most of the subjects were 9 to 17 years of age (n= 2810). 
 
During clinical development, neutralizing antibody titres for each serotype were measured with the 
plaque reduction neutralization test (PRNT) and presented as geometric mean titres (GMTs). 
An association between levels of post-injection 3 geometric mean titres (GMTs) and the probability of 
the disease has been demonstrated in efficacy studies. 
Higher titres post-injection 3 are associated with a lower risk of dengue disease and higher vaccine 
efficacy, although an immunological correlate of protection has not been established. 
 
In the following Tables the dengue serostatus at baseline (before the first injection), was defined as:  
• Dengue seropositivity if the PRNT50 titre ≥ 10 [1/dil] (the lower limit of quantification, 

LLOQ), against at least one serotype. 
• Dengue seronegativity if the PRNT50 titre < the lower limit of quantification against any of the 

4 serotypes. 
 
3.1 Immunogenicity data for subjects 9 to 17 years of age in endemic areas 
 
The post dose 3 GMTs in subjects 9 to 16 years of age in CYD14 and CYD15 are shown in the Table 
6. 
 
Table 6: Immunogenicity for dengue seropositive subjects 9 to 16 years of age in CYD14 and 
CYD15 from endemic areas  
 
  Serotype 1 Serotype 2 Serotype 3 Serotype 4 

Study N 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT 
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT 
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT 
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post-
injection 3 

GMT 
(95%CI) 

CYD14 485 
167 

(138; 202) 

437 

(373; 511) 

319 

(274; 373) 

793 

(704; 892) 

160 

(135; 190) 

443 

(387; 507) 

83.8 

(72.0; 97.6) 

272 

(245; 302) 

CYD15 1048 
278 

(247; 313) 

703 

(634; 781) 

306 

(277; 338) 

860 

(796; 930) 

261 

(235; 289) 

762 

(699; 830) 

73.3 

(66.6; 80.7) 

306 

(286; 328) 
N: number of subjects with available antibody titre for the relevant endpoint 
Dengue seropositive subjects are subjects with titres above or equal to LLOQ against at least one dengue serotype at baseline 
CI: Confidence Interval 
CYD14: Indonesia, Malaysia, the Philippines, Thailand, Vietnam. 
CYD15: Brazil, Colombia, Honduras, Mexico, Puerto Rico. 
 



 15 

 
3.2 Immunogenicity data for subjects 18 to 45 years of age in endemic areas 
 
The immunogenicity of the final formulation of the CYD dengue vaccine in adults aged 18 to 45 years 
in endemic areas was assessed in 3 studies conducted all in Asia-Pacific (CYD22 in Vietnam, CYD28 
in Singapore and CYD47 in India). 
The GMTs post-dose 3 in subjects 18 to 45 years of age are shown in the Table 7 
 
Table 7: Immunogenicity for dengue seropositive subjects 18 to 45 years of age from endemic 
areas  
 

  Serotype 1 Serotype 2 Serotype 3 Serotype 4 

Study N 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT  
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT  
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post-
injection 3 

GMT 
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post-
injection 3 

GMT 
(95%CI) 

CYD22 19 
408 

(205; 810) 

785 

(379; 1626) 

437 

(240; 797) 

937 

(586; 1499) 

192 

(117; 313) 

482 

(357; 651) 

86.5 

(41.2; 182) 

387 

(253; 591) 

CYD28 66 
59.8 

(36.8;97.4) 

235 

(135; 409) 

67.1 

(40.9; 110) 

236 

(144; 387) 

48.4 

(32.9;71.0) 

239 

(166; 342) 

22.1 

(14.7;33.4) 

211 

(155; 287) 

CYD47 109 
324 

(236; 445) 

688 

(524; 901) 

363 

(269; 490) 

644 

(509; 814) 

394 

(299; 519) 

961 

(763;1211) 

80.7 

(613; 106) 

413 

(331; 516) 
N: number of subjects with available antibody titre for the relevant endpoint 
Dengue seropositive subjects are subjects with titres above or equal to LLOQ against at least one dengue serotype at baseline 
CI: Confidence Interval 
CYD28: Low endemic country 
CYD22: Vietnam; CYD28: Singapore; CYD47: India; 
 
The bridging of efficacy is based on above available data and overall results. Immunogenicity data 
available from studies in adults aged 18 to 45 years in endemic regions show that post-injection 3 
GMTs against each serotype are generally higher in adults than in children and adolescents in CYD14 
and CYD15. Therefore, protection is expected in adults in endemics areas although the actual 
magnitude of efficacy relative to that observed in children and adolescents is unknown. 
 
3.3 Long-term persistence of antibodies 
 
A decrease in the GMTs against all 4 serotypes was observed one year after the third injection. Then, 
GMTs stabilize over the next 2 to 4 years and remain superior to pre-vaccination GMTs. The GMTs 
levels depend on age and dengue serostatus at baseline. 
 
5.2 Pharmacokinetic properties  
 
No pharmacokinetic studies have been performed on Dengvaxia. 
 
5.3 Preclinical safety data  
 
Non-clinical safety data revealed no special risks for humans based on a repeated-dose toxicity 
including assessment of local tolerance, and a developmental and reproductive toxicology program. 
There was no shedding of Dengvaxia RNA in a distribution and shedding study, hence no risk of 
dissemination to the environment or transmission from vaccinees. A neurovirulence study shows that 
CYD dengue vaccine is not neurotoxic. 
 
 



 16 

6. PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients  
 
Powder: 
Essential amino acids including Phenylalanine 
Non-essential amino acids 
Arginine hydrochloride 
Sucrose 
Trehalose dihydrate 
Sorbitol (E420) 
Trometamol 
Urea 
Hydrochloric acid and sodium hydroxide for pH adjustment 
 
Solvent: 
Sodium chloride 
Water for injections 
 
6.2 Incompatibilities  
 
Dengvaxia must not be mixed with any other vaccine or medicinal product. 
 
6.3 Shelf life  
 
3 years 
 
After reconstitution with the solvent provided, Dengvaxia should be used immediately. 
 
6.4 Special precautions for storage  
 
Store in a refrigerator (2°C - 8°C). 
 
Do not freeze.  
 
Store in the outer carton in order to protect from light.  
 
For storage conditions after reconstitution of Dengvaxia, see section 6.3. 
 
6.5 Nature and contents of container  
 
• Powder (1 dose) in vial (Type-I glass), with a stopper (halobutyl) and a flip-off cap (aluminium, 

polypropylene) + 0.5 mL of solvent in a pre-filled syringe (Type-I glass), with a plunger stopper 
(halobutyl) and a tip cap (elastomer) with 2 separate needles. 

 
Pack size of 1 or 10. 
 
• Powder (1 dose) in vial (Type-I glass), with a stopper (halobutyl) and a flip-off cap (aluminium, 

polypropylene) + 0.5 mL of solvent in pre-filled syringe (Type-I glass), with a plunger stopper 
(halobutyl) and a tip cap (elastomer). 

 
Pack size of 1 or 10. 
 
The tip caps of the pre-filled syringes contain a natural rubber latex derivative. 
 
Not all pack sizes may be marketed. 
 



 17 

6.6 Special precautions for disposal and other handling  
 
Contact with disinfectants is to be avoided since they may inactivate the vaccine viruses. 
 
Dengvaxia must be reconstituted prior to administration. 
 
Dengvaxia is reconstituted by transferring all of the solvent (0.4% sodium chloride solution) provided 
in the blue-labelled pre-filled syringe into the vial of freeze-dried powder with a yellowish green 
flip-off cap. 
  

1. Attach a sterile needle to the pre-filled syringe for the transfer of the solvent. 
 

2. Transfer the entire content of the pre-filled syringe into the vial containing the powder. 
 

3. Swirl gently until the powder is completely dissolved. 
 
The suspension should be visually inspected prior to administration. After reconstitution, Dengvaxia is 
a clear, colourless liquid with the possible presence of white to translucent particles (of endogenous 
nature).  
 
After complete dissolution, a 0.5 mL dose of the reconstituted suspension is withdrawn into the same 
syringe. For injection, the syringe should be fitted with a new sterile needle. 
 
After reconstitution with the solvent provided, Dengvaxia must be used immediately. 
 
Any unused product or waste material should be disposed of in accordance with local regulations. 
 
 
7. MARKETING AUTHORISATION HOLDER 
 
Sanofi Pasteur  
14 Espace Henry Vallée 
69007 Lyon 
France 
 
 
8. MARKETING AUTHORISATION NUMBER(S) 
 
EU/1/18/1338/001 
EU/1/18/1338/002 
EU/1/18/1338/003 
EU/1/18/1338/004 
 
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
 
Date of first authorisation: 12 December 2018 
 
 
10. DATE OF REVISION OF THE TEXT 
 
 

Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu. 

http://www.ema.europa.eu/


 18 

This medicinal product is subject to additional monitoring. This will allow quick identification of 
new safety information. Healthcare professionals are asked to report any suspected adverse reactions. 
See section 4.8 for how to report adverse reactions. 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Dengvaxia, powder and solvent for suspension for injection in multidose containers 
dengue tetravalent vaccine (live, attenuated) 
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
After reconstitution, one dose (0.5 mL) contains: 
 
Chimeric yellow fever dengue virus serotype 1 (live, attenuated)* ........... 4.5 - 6.0 log10 CCID50/dose** 
Chimeric yellow fever dengue virus serotype 2 (live, attenuated)* ........... 4.5 - 6.0 log10 CCID50/dose** 
Chimeric yellow fever dengue virus serotype 3 (live, attenuated)* ........... 4.5 - 6.0 log10 CCID50/dose** 
Chimeric yellow fever dengue virus serotype 4 (live, attenuated)* ........... 4.5 - 6.0 log10 CCID50/dose** 
 
*Produced in Vero cells by recombinant DNA technology. This product contains genetically modified 
organisms (GMOs). 
**CCID50: 50% Cell Culture Infectious Dose. 
 
Excipients with known effect: (see Section 4.4) 
Phenylalanine………………8 micrograms 
Sorbitol…………….……….1.76 milligrams 
 
For a full list of excipients, see section 6.1. 
 
 
3. PHARMACEUTICAL FORM 
 
Powder and solvent for suspension for injection 
 
Prior to reconstitution, the vaccine is a white, homogenous, freeze-dried powder with possible 
retraction at the base (ring-shaped cake possible). 
 
The solvent is a limpid, colourless solution. 
 
 
4. CLINICAL PARTICULARS 
 
4.1 Therapeutic indications  
 
Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 
and 4 in individuals 9 to 45 years of age with prior dengue virus infection and living in endemic areas 
(see sections 4.2, 4.4 and 4.8). 
 
The use of Dengvaxia should be in accordance with official recommendations. 
 
4.2 Posology and method of administration  



 19 

 
Posology 
 
Children and adults 9 to 45 years of age 
 
The vaccination schedule consists of 3 injections of one reconstituted dose (0.5 mL) to be 
administered at 6-month intervals. 
 
Other paediatric population 
 
Dengvaxia should not be used in children less than 9 years of age (see sections 4.8).  
In vaccinees 2 to 8 years of age with no previous dengue infection, long-term safety follow-up data 
showed an increased risk of dengue disease requiring hospitalisation including clinically severe 
dengue. Available data are not sufficient to confirm the safety and efficacy in individuals previously 
infected by any dengue virus and younger than 9 years. 
 
Method of administration 
 
Previous dengue infection has to be assessed before vaccination by laboratory confirmed history of 
dengue or through an appropriately validated serological test (see section 4.4). 
 
Immunisation should be carried out by subcutaneous (SC) injection preferably in the upper arm in the 
region of deltoid. 
 
Do not administer by intravascular injection.  
 
For instructions on reconstitution of Dengvaxia before administration, see section 6.6. 
 
4.3 Contraindications 
 
• Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or after 

prior administration of Dengvaxia or a vaccine containing the same components. 
 
• Individuals with congenital or acquired cell-mediated immune deficiency, including 

immunosuppressive therapies such as chemotherapy or high doses of systemic corticosteroids 
(e.g. 20mg or 2mg/kg of prednisone for 2 weeks or more) within 4 weeks prior to vaccination. 

 
• Individuals with symptomatic HIV infection or with asymptomatic HIV infection when 

accompanied by evidence of impaired immune function. 
 
• Pregnant women (see section 4.6). 
 
• Breast-feeding women (see section 4.6). 
 
4.4 Special warnings and precautions for use 
 
Protection 
 
A protective immune response with Dengvaxia may not be elicited in all vaccinees. It is recommended 
to continue personal protection measures against mosquito bites after vaccination. 
 
Special patient groups 
 
Individuals who have not been previously infected by dengue virus or for whom this information is 
unknown 
 



 20 

Individuals who have not been previously infected by dengue virus or for whom this information is 
unknown should not be vaccinated because an increased risk of hospitalisation for dengue and 
clinically severe dengue (predominantly grade 1 or 2 Dengue Haemorrhagic Fever) has been observed 
in these individuals during the long-term follow up of clinical trials (see Section 4.8). 
 
In the absence of documented prior dengue virus infection, previous infection has to be confirmed by 
serotesting before vaccination. To avoid vaccination of false positives, only test methods with 
adequate performance in terms of specificity and cross-reactivity based on the local disease 
epidemiology should be used.  
 
Travellers 
 
There are no safety, immunogenicity or efficacy data to support vaccination of individuals living in 
non-endemic areas and travelling to endemic areas, therefore vaccination of these individuals is not 
recommended.  
 
Outbreaks 
 
Dengvaxia should not be used in the context of dengue outbreak in non-endemic regions. 
 
Others 
 
Administration of Dengvaxia must be postponed in individuals suffering from moderate to severe 
febrile or acute disease. 
 
Vaccination should be preceded by a review of the individual's medical history (in particular, previous 
vaccinations and possible adverse reactions which occurred after vaccination). 
 
Appropriate medical treatment and supervision must always be readily available in the event of an 
anaphylactic reaction following administration of the vaccine. 
 
Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to 
injection with a needle. Procedures should be in place to prevent injury from falling and to manage 
syncopal reactions. 
 
Women of childbearing potential have to use effective contraception during at least one month after 
each dose (see section 4.6). 
 
Dengvaxia must not be administered by intravascular injection under any circumstances. 
 
Dengvaxia contains phenylalanine, sodium and sorbitol 
 
Dengvaxia contains 8 micrograms of phenylalanine in each 0.5 ml dose. Phenylalanine may be 
harmful for people with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds 
up because the body cannot remove it properly. 
 
Dengvaxia contains less than 1mmol of sodium (23 mg) per 0.5 ml dose, that is to say essentially 
“sodium-free”. 
 
Dengvaxia contains 1.76 milligrams of sorbitol in each 0.5 ml dose. 
 
Traceability 
 
In order to improve the traceability of biological medicinal products, the name and the batch number 
of the administered product should be clearly recorded. 
 
4.5 Interaction with other medicinal products and other forms of interaction  



 21 

 
For patients receiving treatment with immunoglobulins or blood products containing 
immunoglobulins, such as blood or plasma, it is recommended to wait for at least 6 weeks, and 
preferably for 3 months, following the end of treatment before administering Dengvaxia, in order to 
avoid neutralization of the attenuated viruses contained in the vaccine. 
 
Dengvaxia should not be administered to subjects receiving immunosuppressive therapies such as 
chemotherapy or high doses of systemic corticosteroids within 4 weeks prior to vaccination (see 
section 4.3). 
 
As there are no data on co-administration of Dengvaxia vaccine with other vaccines for the population 
from 9 years and above, the concomitant use of Dengvaxia with other vaccines is not recommended. 
 
4.6 Fertility, pregnancy and lactation  
 
Pregnancy 
 
Animal studies did not indicate any direct or indirect harmful effects with respect to reproductive 
toxicity (see section 5.3). 
 
There is limited amount of data from the use of Dengvaxia in pregnant women. These data are not 
sufficient to conclude on the absence of potential effects of Dengvaxia on pregnancy, embryo-foetal 
development, parturition and post-natal development. 
 
Dengvaxia is a live attenuated vaccine, therefore Dengvaxia is contraindicated during pregnancy (see 
section 4.3).  
 
Women of childbearing potential have to use effective contraception during at least one month after 
each dose. 
 
Breast-feeding 
 
Animal studies did not indicate any direct or indirect harmful effects with respect to lactation. 
There is very limited experience on dengue virus excretion via breast milk. 
Also, considering that Dengvaxia is a live attenuated vaccine and that there is very limited experience 
from post marketing data with Dengvaxia in lactating women, the vaccine is contraindicated during 
lactation (see section 4.3). 

 
Fertility 
 
No specific studies have been performed on fertility. 
Animal studies did not indicate any harmful effects with respect to female fertility (see section 5.3). 
 
4.7 Effects on ability to drive and use machines  
 
Dengvaxia has minor influence on the ability to drive and use machines. 
 
4.8 Undesirable effects  
 
a.  Summary of the safety profile 
 
In subjects 9 to 45 years of age, the most frequently reported reactions whatever the dengue serostatus 
prior to vaccination, were headache (54%), injection site pain (49%), malaise (44%), myalgia (43%), 
asthenia (34%), and fever (16%). 
 



 22 

Adverse reactions occurred within 3 days following vaccination except fever which appears within 14 
days after the injection. The adverse reactions were usually mild to moderate in severity and of short 
duration (0 to 3 days). 
 
Systemic adverse reactions tended to be less frequent after the second and third injections of 
Dengvaxia as compared to the first injection. 
 
Allergic including anaphylactic reactions have been reported very rarely. 
 
Overall, the same adverse reactions but at lower frequencies were observed in dengue seropositive 
subjects. 
b.  Tabulated list of adverse reactions  
 
Adverse reactions are listed according to the following frequency categories:  
Very common: ≥ 1/10 
Common: ≥ 1/100 to < 1/10 
Uncommon: ≥ 1/1000 to < 1/100 
Rare: ≥ 1/10 000 to < 1/1000 
Very rare: (<1/10 000) 
 
Adverse reactions collected within 28 days after any injection during clinical studies from 9 to 45 
years of age, on a reactogenicity subset of 1306 adults and 3067 children, and adverse reactions 
observed during commercial use are presented in Table 1 for children 9 to 17 years old and in Table 2 
for adults 18 to 45 years old.  
 
Table 1: Adverse reactions from Clinical Studies and reported during commercial use in 
children (9 to 17 years old) 
 

System Organ Class  Frequency  Adverse Events  
Infections and infestations  Rare Upper respiratory tract infection 

Immune system disorders Very rare Allergic including anaphylactic reactions* 

Nervous system disorders 
 

Very common Headache 
Rare  Dizziness 

Respiratory, thoracic and 
mediastinal disorders 

Rare  Oropharyngeal pain 
Cough 
Rhinorrhoea 

Gastrointestinal disorders Rare  Nausea 

Skin and subcutaneous 
tissue disorders 

Uncommon Urticaria 
Rare  Rash 

Musculoskeletal and 
connective tissue disorders 

Very common Myalgia 
Rare  Neck pain 

General disorders and 
administration site 
conditions 

Very common Injection site pain 
Malaise 
Asthenia 
Fever 

Common Injection site reactions (erythema, swelling) 
Uncommon Injection site reactions (hematoma, pruritus) 

Injection site induration 
* Adverse reactions from spontaneous reporting. 
 



 23 

Table 2: Adverse reactions from Clinical Studies and reported during commercial use in adults 
(18 to 45 years old) 
 

System Organ Class  Frequency  Adverse Events  
Infections and infestations  Uncommon Upper respiratory tract infection 

Nasopharyngitis 
Blood and lymphatic tissue 
disorders 

Uncommon Lymphadenopathy 

Immune system disorders Very rare Allergic including anaphylactic reactions* 

Nervous system disorders 
 

Very common Headache 
Uncommon Dizziness 

 
Respiratory, thoracic and 
mediastinal disorders 

Uncommon Oropharyngeal pain 
Cough 
 

Gastrointestinal disorders Uncommon Nausea 
Dry mouth 

Skin and subcutaneous 
tissue disorders 

Uncommon Rash 
Rash generalised 

Musculoskeletal and 
connective tissue disorders 

Very common Myalgia 
Uncommon Neck pain 

Arthralgia 
General disorders and 
administration site 
conditions 

Very common Injection site pain 
Malaise 
Asthenia 

Common Fever 
Injection site reactions (erythema, hematoma, 
swelling, pruritus) 

Uncommon Injection site induration 
Injection site warmth 
Chills 
Fatigue 

* Adverse reactions from spontaneous reporting. 
 
c.  Hospitalised and/or clinically severe dengue fever in long-term safety follow-up data 
 
In an exploratory analysis of the long-term follow up from the first injection in three efficacy studies, 
an increased risk of hospitalisation for dengue including clinically severe dengue (predominantly 
Dengue Haemorrhagic Fever grade 1 or 2 [WHO 1997]) has been observed in vaccinees with no 
previous dengue infection. Over a period of 6 years, in subjects with no previous dengue infection, the 
risk of severe dengue is increased by 2.41 fold (95% CI: 0.50; 11.75) in subjects 9 to 16 years of age 
vaccinated with Dengvaxia as compared to non-vaccinated subjects in the same age group. In subjects 
9 years of age or older, it was estimated that during a 6 year follow-up about 5 additional hospitalized 
dengue cases or 3 additional severe dengue cases per 1000 vaccinees with no previous dengue 
infection could occur following vaccination. Estimates from the long-term analysis suggest the onset 
of increased risk was mainly during the 3rd year following the first injection.  
This increased risk was not observed in individuals who have been previously infected by dengue 
virus, where it was estimated that 16 hospitalized dengue cases or 4 severe dengue cases could be 
prevented per 1000 vaccinees with previous dengue infection during 6 years of follow up from the first 
injection. 
  
The estimations described above for a 6 year period are derived from data obtained in the pivotal 
clinical trials in countries with a particular dengue seroprevalence and epidemiological context. These 
figures may not be extrapolated to other regions with different seroprevalence and epidemiological 
situations. 



 24 

 
d.  Paediatric population 
 
Paediatric data in subjects 9 to 17 years of age 
 
In paediatric population, fever has been observed with a higher frequency (very common) than in 
adults (common). 
 
Urticaria (uncommon) was only reported in subjects 9 to 17 years of age (none in adults). 
 
Paediatric data in subjects below 9 years of age, i.e., outside the age indication 
 
The reactogenicity subset in subjects below 9 years of age includes 2960 subjects as follows: 1287 
subjects below 2 years of age, 905 subjects between 2 and 5 years of age and 768 subjects between 6 
and 8 years of age. 
 
In subjects 2 to 8 years of age, as compared to subjects above 9 years of age, injection site erythema 
and swelling were more frequently reported (frequency: very common), and additional adverse events 
were reported (frequency: uncommon): injection site haemorrhage, decreased appetite and vomiting. 
 
In subjects 2 to 8 years of age, with no previous dengue infection, long-term safety follow-up data 
showed an increased risk of dengue disease requiring hospitalisation including clinically severe 
dengue in vaccinated subjects as compared to non-vaccinated subjects. 
 
In subjects below 2 years of age, the most frequently reported adverse reactions following any 
injection of Dengvaxia were fever, irritability, appetite lost, abnormal crying and injection site 
tenderness. 
 
Reporting of suspected adverse reactions 
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 
professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V. 
 
4.9 Overdose  
 
No cases of overdose have been reported. 
 
 
5. PHARMACOLOGICAL PROPERTIES 
 
5.1  Pharmacodynamic properties  
 
Pharmacotherapeutic group: Vaccines, Viral vaccines, ATC code: J07BX/ Not Yet assigned 
 
1. Mechanism of action 
 
Dengvaxia contains live attenuated viruses. Following administration, the viruses replicate locally and 
elicit neutralizing antibodies and cell-mediated immune responses against the four dengue virus 
serotypes (see detailed data below, subsection 3). 
 
2. Clinical efficacy 
 
The clinical efficacy of Dengvaxia was assessed in 3 studies: one supportive Phase IIb efficacy study 
(CYD23) in Thailand, and 2 pivotal large-scale Phase III efficacy studies, CYD14 in Asia (Indonesia, 
Malaysia, the Philippines, Thailand, Vietnam) and CYD15 in Latin America (Brazil, Colombia, 
Honduras, Mexico, Puerto Rico). 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 25 

 
The Control Group in dengue studies was defined as subjects who received at least one injection of 
placebo or comparator vaccine. 
 
In the Phase IIb study, a total of 4002 subjects aged 4 to 11 years were randomised to receive 
Dengvaxia or a control, regardless of previous dengue infection. Efficacy in subjects 9 to 11 years of 
age was assessed in 1554 subjects (1032 in vaccine group and 522 in Control Group). 
 
In the two pivotal Phase III studies (CYD14 and CYD15), a total of approximately 31000 subjects 
aged 2 to 16 years were randomised to receive either Dengvaxia or placebo, regardless of previous 
dengue infection. Efficacy in subjects 9 years of age and older was assessed in 17 230 subjects who 
received Dengvaxia (3316 subjects in CYD14 and 13914 in CYD15) and 8596 subjects who received 
placebo (1656 in CYD14 and 6940 in CYD15). 
 
At the start of the CYD14 and CYD15 trials, dengue seroprevalence for the overall population at the 
trial sites ranged from 52.8%-81.1% in CYD14 (Asia-Pacific) and 55.7%-92.7% in CYD15 (Latin 
America). 
 
The efficacy was assessed during an Active Phase of 25 months, in which surveillance was designed 
to maximize the detection of all symptomatic virologically-confirmed dengue (VCD) cases regardless 
of the severity. The active detection of symptomatic dengue cases started on the day of the first 
injection and lasted until each subject had been followed for at least 13 months after the third 
injection. This phase includes therefore the primary endpoint observation period from 28 days after the 
third injection up to the end of the Active Phase. 
 
For the primary endpoint, the incidence of symptomatic VCD cases occurring during the 12-month 
period from 28 days after the third injection was compared to the Control Group. 
 
Exploratory vaccine efficacy analyses according to dengue serostatus measured by plaque reduction 
neutralization test (PRNT50) at baseline (before the first injection) were performed in the 
immunogenicity subset of 2000 subjects each in CYD14 and CYD15 and 300 subjects in CYD23. Of 
the 2930 subjects 9 to 16 years old in this subset (approximately 80%) who were dengue seropositive 
at baseline, 1974 subjects received the vaccine (901 subjects in CYD14 and 1073 in CYD15) and 956 
subjects received placebo (444 in CYD14 and 512 in CYD15) (see also subsection 3). 
 
2.1 Clinical efficacy data for subjects 9 to 16 years of age in endemic areas, any serostatus at 
baseline 
 
The Vaccine Efficacy (VE) results according to the primary endpoint (symptomatic VCD cases 
occurring during the 12-month period starting from 28 days after the third injection) in subjects 9 to 16 



 26 

years of age (any serostatus at baseline) are shown in Table 3 for studies CYD14, CYD15 and 
CYD23. 
 
Table 3: VE against symptomatic VCD cases over the 12-month period starting from 28 days 
after the third injection due to any of the 4 serotypes in subjects 9 to 16 years (any serostatus at 
baseline). 
 
 

CYD14 CYD15 CYD23 Pooled CYD14+CYD15 

Pooled* 
CYD14+CYD15+ 

CYD23 

 Vaccine group 
Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Cases / 
person-
years 

34 / 
3199 

55 / 
1585 

185 / 
12458 

236 / 
6157 

6 / 
1033 

10 / 
514 

219 / 
15657 

291 / 
7742 

225 / 
16690 

301 / 
8256 

VE % 
(95%CI) 

69.4  
(52.2; 80.6) 

61.3  
(52.8; 68.2) 

70.1 
(9.3; 91.1) 

62.8  
(55.7; 68.8) 

63.0 
(56.1; 68.9) 

N: number of subjects per study 
Cases: number of subjects with at least one symptomatic virologically-confirmed dengue episode in the considered period. 
Person-years: sum of time-at-risk (in years) for the subjects during the study period. 
CI: confidence interval. 
*Pooled results of CYD14, 15 and 23 need to be interpreted cautiously because of differences in the Dengue confirmatory 
test and acute febrile illness definition between CYD14/15 and CYD23. 
 
In subjects 9 to 16 years of age, the efficacy of Dengvaxia against symptomatic virologically-
confirmed dengue (VCD) cases due to any of the 4 serotypes was demonstrated in all three studies, 
CYD14, CYD15 and CYD23 (see Table 3). 
 
The Vaccine Efficacy (VE) against symptomatic VCD, severe and hospitalised VCD during the 25-
month period after the first injection, which were secondary objectives, in subjects 9 to 16 years of age 
are shown in Table 4 for any serostatus at baseline for studies CYD14, CYD15 and CYD23. For 
severe VCD cases, two types of endpoints were considered: clinically severe VCD cases and VCD 
cases that met the 1997 WHO criteria for Dengue Haemorrhagic Fever (DHF).  
Vaccine efficacy was demonstrated for these endpoints in CYD14 and CYD15 (see Table 4). 
 
The vaccine efficacy against symptomatic VCD is moderate for serotypes 1 and 2 and higher for 
serotypes 3 and 4 (see Table 4). 
 



 27 

Table 4: VE against symptomatic, Hospitalised or Severe VCD over the 25-month period after 
the first injection in subjects 9 to 16 years of age (any serostatus at baseline) 
 

 
CYD14 CYD15 Pooled 

CYD14+CYD15 
CYD23 

Pooled* 
CYD14+CYD15+ 

CYD23 

VE % 
(95% CI) 

VE % 
(95% CI) 

VE % 
(95% CI) 

VE % 
(95%CI) 

VE % 
(95% CI) 

N=4972 N=20854 N=25826 N = 1554 N = 27380 
Symptomatic VCD 

Any serotype 67.8 
(57.7; 75.6) 

64.7 
(58.7; 69.8) 

65.6 
(60.7; 69.9) 

43.3 
(-18.9; 72.7) 

64.9 
(60.0; 69.2) 

Serotype 1 65.7 
(46.6; 78.2) 

54.8 
(40.2; 65.9) 

58.4 
(47.7; 66.9) 

78.4 
(5.4; 96.4) 

59.2 
(48.9; 67.4) 

Serotype 2 36.8 
(-10.1; 63.3) 

50.2 
(31.8; 63.6) 

47.1 
(31.3; 59.2) 

5.9 
(-178.6; 65.1) 

44.6 
(28.9; 56.9) 

Serotype 3 69.5 
(31.9; 87.0) 

74.2 
(63.9; 81.7) 

73.6 
(64.4; 80.4) 

-1.2 
(-5870.2; 94.7) 

73.0 
(63.7; 79.9) 

Serotype 4 87.9 
(75.5; 94.6) 

80.9 
(70.9; 87.7) 

83.2 
(76.2; 88.2) 

100.0 
(-1873.3; 

100.0) 

83.3 
(76.4; 88.2) 

Hospitalised 
VCD† 

81.6 
(60.7; 92.0) 

80.3 
(64.7; 89.5) 

80.8 
(70.1; 87.7) 

72.5 
(19.0; 91.7) 

79.7 
(69.6; 86.5) 

Clinically severe 
VCD cases† 

90.9 
(58.4; 99.0) 

95.5 
(68.8; 99.9) 

93.2 
(77.3; 98.0) 

49.4 
(-3870.3; 99.4) 

91.3 
(74.9; 97.0) 

DHF meeting 
any WHO 
criteria 

90.9 
(58.4; 99.0) 

95.0 
(64.9; 99.9) 

92.9 
(76.1; 97.9) 

100.0 
(-1871.5; 

100.0) 

93.2 
(77.3; 98.0) 

N: number of subjects per study 
CI: confidence interval. 
VE is calculated using density incidence (cases per 100 person-years at risk) 
* Pooled results of CYD14, 15 and 23 need to be interpreted cautiously because of differences in the Dengue confirmatory 
test and acute febrile illness definition between CYD14/15 and CYD23. 
†The efficacy against hospitalised and severe VCD was not a primary objective and cut-off thresholds to define statistical 
significance were not pre-specified. 
 



 28 

2.2 Clinical efficacy data for subjects 9 to 16 years of age in endemic areas, dengue seropositive at 
baseline 
 
The Vaccine Efficacy (VE) results according to exploratory analysis of symptomatic VCD cases 
occurring during the 12-month period starting from 28 days after the third injection in subjects 9 to 16 
years of age, seropositives at baseline are shown in Table 5 for the immunogenicity subset of studies 
CYD14, CYD15 and CYD23. 
 
Table 5: VE against symptomatic VCD cases over the 12-month period starting from 28 days 
after the third injection due to any of the 4 serotypes in subjects 9 to 16 years (dengue 
seropositive at baseline). 
 

 
CYD14 CYD15 CYD23 Pooled CYD14+CYD15 

Pooled * 
CYD14+CYD15+ 

CYD23 

 Vaccine group 
Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Vaccine 
group 

Control 
group 

Cases / 
person-
years 

4/471 9/241 7/1002 17/472 0/55 0/19 11/1473 26/713 11/1528 26/732 

VE % 
(95%CI) 

77.2 
(18.3; 94.9) 

80.6 
(50.7; 93.2) NC 

79.4 
(58.4; 89.8) 

79.4 
(58.4; 89.8) 

N: number of subjects per study 
Cases: number of subjects with at least one symptomatic virologically-confirmed dengue episode in the considered period. 
Person-years: sum of time-at-risk (in years) for the subjects during the study period. 
CI: confidence interval. 
NC: Not computed (the absence of cases in vaccine and control group does not permit to calculate VE nor CI) 
*Pooled results of CYD14, 15 and 23 need to be interpreted cautiously because of differences in the Dengue confirmatory 
test and acute febrile illness definition between CYD14/15 and CYD23. 
 
The Vaccine Efficacy (VE) against symptomatic VCD during the 25-month period after the first 
injection, in subjects 9 to 16 years of age dengue seropositives at baseline and for the immunogenicity 
subset for pooled CYD14 + CYD15+CYD23, is estimated at 81.9% (95% CI: 67.2 ; 90.0). 
 
In subjects 9 through 16 years of age dengue seropositive at baseline (immunogenicity subset), one 
clinically severe VCD case and one WHO DHF VCD case was reported during the 25-month period 
after the first injection in the control group in each individual study (CYD14 and CYD15) versus none 
in the vaccine group. Four hospitalized VCD cases in CYD14 and two hospitalized VCD cases in 
CYD15 were reported in the control group versus none in the vaccine group. These data are 
inconclusive due to the low number of cases in the immunogenicity subset. However, the extrapolated 
vaccine efficacy (1- Hazard Ratio), obtained from an exploratory analysis (pooled CYD14 + CYD15 + 
CYD23) over 25-month period after the first injection, is estimated at 89.2% (95% CI: 78.5; 94.6) for 
hospitalized VCD and 95.3% (95% CI: 68.9; 99.3) for severe VCD. 
 
2.3 Clinical efficacy data for subjects 17 to 45 years of age in endemic areas 
 
No clinical efficacy study has been done in subjects from 17 to 45 years from endemic areas. The 
clinical efficacy of the vaccine is based on bridging of immunogenicity data (see below section 3.2). 
 
2.4 Other paediatric data from efficacy studies in subjects 2 through 8 years of age, i.e., outside the 
age indication 
 
Efficacy in subjects 2 to 8 years of age was assessed in 2443 subjects (1634 in vaccine group and 809 
in control group) in phase IIb study and in 5300 subjects (3532 subjects in vaccine group and 1768 in 
control group) in the pivotal Phase III study (CYD14). Vaccine efficacy against symptomatic VCD 
cases over the 12-month  period starting from 28 days after the third injection due to any of the 4 
serotypes was 40.5% (95% CI: 22.7; 54.2) (pooled CYD14+CYD23). Vaccine Efficacy against 



 29 

symptomatic, severe and hospitalized VCD during the 25-month period after the first injection due to 
any serotype (pooled CYD14+CYD23), was respectively 42.2% (95% CI: 30.6; 51.8), 45.1% (95% 
CI: 29.3; 76.7),  47.6% (95% CI: 23.7; 64.0).  
 
2.5 Long-term protection 
 
During a period of 6 years after the first injection, in subjects 9 years of age and above with previous 
dengue infection, the extrapolated vaccine efficacy (1-Hazard Ratio)*100 (obtained from an 
exploratory analysis) is estimated at 80 (95% CI: 69; 87) for hospitalized VCD and 84 (95% CI: 61; 
94) for severe VCD. 
 
3. Immunogenicity 
 
During clinical development, immunogenicity data were collected in a total of approximately 
5700 subjects 9 months to 60 years of age that received at least one injection of the vaccine. 
 
Among these 5700 subjects, a total of 3104 subjects 9 to 45 years of age from endemic areas received 
at least one injection of Dengvaxia. Most of the subjects were 9 to 17 years of age (n= 2810). 
 
During clinical development, neutralizing antibody titres for each serotype were measured with the 
plaque reduction neutralization test (PRNT) and presented as geometric mean titres (GMTs). 
An association between levels of post-injection 3 geometric mean titres (GMTs) and the probability of 
the disease has been demonstrated in efficacy studies. .  
Higher titres post-injection 3 are associated with a lower risk of dengue disease and higher vaccine 
efficacy, although an immunological correlate of protection has not been established. 
 
In the following Tables the dengue serostatus at baseline (before the first injection), was defined as:  
• Dengue seropositivity if the PRNT50 titre ≥ 10 [1/dil] (the lower limit of quantification, 

LLOQ), against at least one serotype. 
• Dengue seronegativity if the PRNT50 titre < the lower limit of quantification against any of the 

4 serotypes. 
 
3.1 Immunogenicity data for subjects 9 to 17 years of age in endemic areas 
 
The post dose 3 GMTs in subjects 9 to 16 years of age in CYD14 and CYD15 are shown in the Table 
6. 

Table 6: Immunogenicity for dengue seropositive subjects 9 to 16 years of age in CYD14 and 
CYD15 from endemic areas  
 

  Serotype 1 Serotype 2 Serotype 3 Serotype 4 

Study N 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT 
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT 
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT 
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post-
injection 3 

GMT 
(95%CI) 

CYD14 485 
167 

(138; 202) 

437 

(373; 511) 

319 

(274; 373) 

793 

(704; 892) 

160 

(135; 190) 

443 

(387; 507) 

83.8 

(72.0; 97.6) 

272 

(245; 302) 

CYD15 1048 
278 

(247; 313) 

703 

(634; 781) 

306 

(277; 338) 

860 

(796; 930) 

261 

(235; 289) 

762 

(699; 830) 

73.3 

(66.6; 80.7) 

306 

(286; 328) 
N: number of subjects with available antibody titre for the relevant endpoint 
Dengue seropositive subjects are subjects with titres above or equal to LLOQ against at least one dengue serotype at baseline 
CI: Confidence Interval 
CYD14: Indonesia, Malaysia, the Philippines, Thailand, Vietnam. 
CYD15: Brazil, Colombia, Honduras, Mexico, Puerto Rico. 
 



 30 

 
3.2 Immunogenicity data for subjects 18 to 45 years of age in endemic areas 
 
The immunogenicity of the final formulation of the CYD dengue vaccine in adults aged 18 to 45 years 
in endemic areas was assessed in 3 studies conducted all in Asia-Pacific (CYD22 in Vietnam, CYD28 
in Singapore and CYD47 in India). 
The GMTs post-dose 3 in subjects 18 to 45 years of age are shown in the Table 7 
 
Table 7: Immunogenicity for dengue seropositive subjects 18 to 45 years of age from endemic 
areas  
 

  Serotype 1 Serotype 2 Serotype 3 Serotype 4 

Study N 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT  
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post- 
injection 3 

GMT  
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post-
injection 3 

GMT 
(95%CI) 

Pre- 
injection 1 

GMT 
(95%CI) 

Post-
injection 3 

GMT 
(95%CI) 

CYD22 19 
408 

(205; 810) 

785 

(379; 1626) 

437 

(240; 797) 

937 

(586; 1499) 

192 

(117; 313) 

482 

(357; 651) 

86.5 

(41.2; 182) 

387 

(253; 591) 

CYD28 66 
59.8 

(36.8;97.4) 

235 

(135; 409) 

67.1 

(40.9; 110) 

236 

(144; 387) 

48.4 

(32.9;71.0) 

239 

(166; 342) 

22.1 

(14.7;33.4) 

211 

(155; 287) 

CYD47 109 
324 

(236; 445) 

688 

(524; 901) 

363 

(269; 490) 

644 

(509; 814) 

394 

(299; 519) 

961 

(763;1211) 

80.7 

(613; 106) 

413 

(331; 516) 
N: number of subjects with available antibody titre for the relevant endpoint 
Dengue seropositive subjects are subjects with titres above or equal to LLOQ against at least one dengue serotype at baseline 
CI: Confidence Interval 
CYD28: Low endemic country 
CYD22: Vietnam; CYD28: Singapore; CYD47: India; 
 
The bridging of efficacy is based on above available data and overall results. Immunogenicity data 
available from studies in adults aged 18 to 45 years in endemic regions show that post-injection 3 
GMTs against each serotype are generally higher in adults than in children and adolescents in CYD14 
and CYD15. Therefore, protection is expected in adults in endemics areas although the actual 
magnitude of efficacy relative to that observed in children and adolescents is unknown. 
 
3.3 Long-term persistence of antibodies 
 
A decrease in the GMTs against all 4 serotypes was observed one year after the third injection. Then, 
GMTs stabilize over the next 2 to 4 years and remain superior to pre-vaccination GMTs. The GMTs 
levels depend on age and dengue serostatus at baseline. 
 
5.2 Pharmacokinetic properties  
 
No pharmacokinetic studies have been performed on Dengvaxia. 
 
5.3 Preclinical safety data  
 
Non-clinical safety data revealed no special risks for humans based on a repeated-dose toxicity 
including assessment of local tolerance, and a developmental and reproductive toxicology program. 
There was no shedding of Dengvaxia RNA in a distribution and shedding study, hence no risk of 
dissemination to the environment or transmission from vaccinees. A neurovirulence study shows that 
CYD dengue vaccine is not neurotoxic. 
 
 



 31 

6. PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients  
 
Powder: 
Essential amino acids including Phenylalanine 
Non-essential amino acids 
Arginine hydrochloride 
Sucrose 
Trehalose dihydrate 
Sorbitol (E420) 
Trometamol 
Urea 
Hydrochloric acid and sodium hydroxide for pH adjustment 
 
Solvent: 
Sodium chloride 
Water for injections 
 
6.2 Incompatibilities  
 
Dengvaxia must not be mixed with any other vaccine or medicinal product. 
 
6.3 Shelf life  
 
3 years 
 
After reconstitution with the solvent provided, Dengvaxia must be kept in a refrigerator (2°C to 8°C) 
and must be used within 6 hours. 
 
6.4 Special precautions for storage  
 
Store in a refrigerator (2°C - 8°C). 
 
Do not freeze.  
 
Store in the outer carton in order to protect from light.  
 
For storage conditions after reconstitution of Dengvaxia, see section 6.3. 
 
6.5 Nature and contents of container  
 
• Powder (5 doses) in vial (Type-I glass), with a stopper (halobutyl) and a flip-off cap 

(aluminium, polypropylene) + 2.5 mL of solvent in vial (Type-I glass), with a stopper 
(halobutyl) and a flip-off cap (aluminium, polypropylene). 

 
Pack size of 5. 
 



 32 

6.6 Special precautions for disposal and other handling  
 
Contact with disinfectants is to be avoided since they may inactivate the vaccine viruses. 
 
Dengvaxia must be reconstituted prior to administration. 
 
Dengvaxia is reconstituted by transferring all of the solvent (0.9% sodium chloride solution) provided 
in the 5-dose vial with a dark grey flip-off cap into the 5-dose vial of freeze-dried powder with a 
medium brown flip-off cap, using a sterile syringe and needle.  
  

1. Use a sterile syringe and needle for the transfer of the solvent. 
 

2. Transfer the entire content of the solvent vial (with a dark gray flip-off cap) into the vial 
containing the powder (medium brown flip-off cap). 

 
3. Swirl gently until the powder is completely dissolved. 

 
The suspension should be visually inspected prior to administration. After reconstitution, Dengvaxia is 
a clear, colourless liquid with the possible presence of white to translucent particles (of endogenous 
nature).  
 
After complete dissolution, a 0.5 mL dose of the reconstituted suspension is withdrawn into the same 
syringe. A new sterile syringe and needle should be used for withdrawal of each of the 5 doses. The 
recommended size of the needle to be used is 23G or 25G. 
 
Before each injection, the reconstituted suspension should be gently swirled once again. 
 
After reconstitution with the solvent provided, Dengvaxia must be used within 6 hours.  
 
Partially used vials must be kept between 2°C and 8°C (in a refrigerator) and protected from light. 
 
Any remaining vaccine doses should be discarded at the end of the immunization session or within 6 
hours after reconstitution, whichever comes first. 
 
A partially used multidose vial must be discarded immediately if: 
• Sterile dose withdrawal has not been fully observed. 
• A new sterile syringe and needle were not used for reconstitution or withdrawal of each of the 

previous doses. 
• There is any suspicion that the partially used vial has been contaminated. 
• There is visible evidence of contamination, such as a change in appearance. 
 
Any unused product or waste material should be disposed of in accordance with local regulations. 
 
 
7. MARKETING AUTHORISATION HOLDER 
 
Sanofi Pasteur  
14 Espace Henry Vallée  
69007 Lyon  
France 
 
 
8. MARKETING AUTHORISATION NUMBER(S) 
 
EU/1/18/1338/005 
 
 



 33 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
 
Date of first authorisation: 12 December 2018 
 
 
10. DATE OF REVISION OF THE TEXT 
 
 

Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu. 

  

http://www.ema.europa.eu/


 34 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX II 

 

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE 
SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE 
FOR BATCH RELEASE  

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY 
AND USE 

 
C. OTHER CONDITIONS AND REQUIREMENTS OF THE 

MARKETING AUTHORISATION 
 
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO 

THE SAFE AND EFFECTIVE USE OF THE MEDICINAL 
PRODUCT 

 

 



 35 

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND 
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 

Name and address of the manufacturer(s) of the biological active substance(s)  

Sanofi Pasteur NVL  
31-33 quai Armand Barbès 
69250 Neuville-sur-Saône 
France 
 
Sanofi Pasteur 
1541 avenue Marcel Mérieux 
69280 Marcy l’Etoile 
France 
 

Name and address of the manufacturer(s) responsible for batch release 

Sanofi Pasteur NVL  
31-33 quai Armand Barbès 
69250 Neuville-sur-Saône 
France 
 
Sanofi Pasteur 
Parc Industriel d’Incarville 
27100 Val de Reuil 
France 
 
The printed package leaflet of the medicinal product must state the name and address of the 
manufacturer responsible for the release of the concerned batch. 
 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

Medicinal product subject to medical prescription. 
 

• Official batch release 
 

In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be 
undertaken by a state laboratory or a laboratory designated for that purpose. 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
AUTHORISATION  

• Periodic safety update reports (PSURs) 
 

The requirements for submission of PSURs for this medicinal product are set out in the list of 
Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and 
any subsequent updates published on the European medicines web-portal. 

The marketing authorisation holder (MAH) shall submit the first PSURs for this product within 6 
months following authorisation. 
 



 36 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 
• Risk management plan (RMP) 
 

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities 
and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing 
authorisation and any agreed subsequent updates of the RMP. 

An updated RMP should be submitted: 

• At the request of the European Medicines Agency; 

• Whenever the risk management system is modified, especially as the result of new 
information being received that may lead to a significant change to the benefit/risk profile or 
as the result of an important (pharmacovigilance or risk minimisation) milestone being 
reached.  

 
• Additional risk minimisation measures 
 

Prior to launch of Dengvaxia in each Member State the Marketing Authorisation Holder (MAH) must 
agree the content and format of the educational programme, including communication media, 
distribution modalities, and any other aspects of the programme, with the National Competent 
Authority.  

The MAH shall ensure that in each Member State where Dengvaxia is marketed, all healthcare 
professionals who are expected to use Dengvaxia have access to/are provided with the following 
educational package: 

• Physician educational material 

The physician educational material should contain: 

• The Summary of Product Characteristics 

• Guide for healthcare professionals 

The Guide for healthcare professionals shall contain the following key elements: 

o That there is an increased risk of severe and/or hospitalized dengue following vaccination 
in individuals not previously infected by dengue virus; 

o That healthcare professionals have to document before vaccination the previous dengue 
infection, which has to be assessed by laboratory confirmed history of dengue or through 
serotesting; 

o The healthcare professionals should be aware that the test they use should have adequate 
performance in terms of specificity and cross-reactivity based on the local disease 
epidemiology. 

o That healthcare professionals should be aware of dengue early warning signs.        

 
  



 37 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX III  
 

LABELLING AND PACKAGE LEAFLET  
  



 38 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

A. LABELLING  



 39 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
 
Powder (1 dose) in vial + 0.5 mL of solvent in pre-filled syringe with 2 separate needles.  
Powder (1 dose) in vial + 0.5 mL of solvent in pre-filled syringe. 
Pack size of 1 or 10. 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Dengvaxia, powder and solvent for suspension for injection in pre-filled syringe 
dengue tetravalent vaccine (live, attenuated) 
 
 
2. STATEMENT OF ACTIVE SUBSTANCES 
 
After reconstitution, one dose (0.5 mL) contains 4.5 - 6.0 log10 CCID50 of each serotype of the 
chimeric yellow fever dengue virus (1, 2, 3 and 4) (live, attenuated). 
 
 
3. LIST OF EXCIPIENTS 
 
Excipients: 
 
Powder: essential amino acids including Phenylalanine, non-essential amino acids, Arginine 
hydrochloride, sucrose, Trehalose dihydrate, Sorbitol, trometamol, urea, hydrochloric acid, sodium 
hydroxide. 
 
Solvent: sodium chloride (0.4%), water for injections. 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Powder (1 dose) in vial + 0.5 mL of solvent in pre-filled syringe with 2 separate needles 
Powder (1 dose) in vial + 0.5 mL of solvent in pre-filled syringe 
Pack size of 1 or 10 
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Subcutaneous use after reconstitution. 
Read the package leaflet before use and for reconstitution instructions. 
Reconstitute Dengvaxia with the solvent provided.  
 
More information on dengue and vaccination 
QR Code to be included + http://qr.sanofi.com/dengvaxia 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN  
 
Keep out of the sight and reach of children. 
 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 

http://qr.sanofi.com/dengvaxia


 40 

 
8. EXPIRY DATE 
 
EXP {MM/YYYY} 
 
 
9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator.  
Do not freeze. Protect from light. 
After reconstitution, use immediately.  
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Sanofi Pasteur 
14 Espace Henry Vallée 
69007 Lyon 
France 
 
 
12. MARKETING AUTHORISATION NUMBER(S) 
 
EU/1/18/1338/001 
EU/1/18/1338/002 
EU/1/18/1338/003 
EU/1/18/1338/004 
 
13. BATCH NUMBER 
 
Lot 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted. 
 
 
17. UNIQUE IDENTIFIER – 2D BARCODE 
 
2D barcode carrying the unique identifier included. 
 
 



 41 

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA 
 
PC 
SN 
NN 
  



 42 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
 
Dengvaxia - Powder (1 dose) in vial 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Dengvaxia, powder for injection 
dengue tetravalent vaccine (live, attenuated) 
SC 
 
 
2. METHOD OF ADMINISTRATION 
 
 
3. EXPIRY DATE 
 
EXP {MM/YYYY} 
 
 
4. BATCH NUMBER 
 
Lot  
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
1 Dose 
1D 
 
 
6. OTHER 
 
 



 43 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
 
Dengvaxia - Solvent in a pre-filled syringe (0.5 mL) 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Solvent for reconstitution of Dengvaxia 
NaCl (0.4%) 
 
 
2. METHOD OF ADMINISTRATION 
 
 
3. EXPIRY DATE 
 
EXP {MM/YYYY} 
 
 
4. BATCH NUMBER  
 
Lot  
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
1 Dose - 0.5 mL 
1D 
 
 
6. OTHER 
 
 



 44 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
 
Dengvaxia - Powder (5 doses) in vial + 2.5 mL of solvent in vial. Pack size of 5 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Dengvaxia, powder and solvent for suspension for injection in multidose containers 
dengue tetravalent vaccine (live, attenuated) 
 
 
2. STATEMENT OF ACTIVE SUBSTANCES 
 
After reconstitution, one dose (0.5 mL) contains 4.5 - 6.0 log10 CCID50 of each serotype of the 
chimeric yellow fever dengue virus (1, 2, 3 and 4) (live, attenuated). 
 
 
3. LIST OF EXCIPIENTS 
 
Excipients: 
 
Powder: essential amino acids including Phenylalanine, non-essential amino acids, Arginine 
hydrochloride, sucrose, Trehalose dihydrate, Sorbitol, trometamol, urea, hydrochloric acid, sodium 
hydroxide. 
 
Solvent: sodium chloride (0.9%), water for injections. 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Powder (5 doses) in vial + 2.5 mL of solvent in vial 
Pack size of 5. 
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Subcutaneous use after reconstitution. 
Read the package leaflet before use and for reconstitution instructions. 
Reconstitute Dengvaxia with the solvent provided.  
 
More information on dengue and vaccination 
QR Code to be included + http://qr.sanofi.com/dengvaxia 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN  
 
Keep out of the sight and reach of children. 
 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
 

http://qr.sanofi.com/dengvaxia


 45 

8. EXPIRY DATE 
 
EXP {MM/YYYY} 
 
 
9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator.  
Do not freeze. Protect from light. 
After reconstitution, use within 6 hours if stored between 2°C and 8°C.  
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Sanofi Pasteur  
14 Espace Henry Vallée 
69007 Lyon  
France 
 
 
12. MARKETING AUTHORISATION NUMBER(S) 
 
EU/1/18/1338/005 
 
 
13. BATCH NUMBER 
 
Lot 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted. 
 
 
17. UNIQUE IDENTIFIER – 2D BARCODE 
 
2D barcode carrying the unique identifier included. 
 
 
18. UNIQUE IDENTIFIER – HUMAN READABLE DATA 
 
PC 



 46 

SN 
NN 
  



 47 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
 
Dengvaxia - Powder (5 doses) in vial 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Dengvaxia, powder for injection 
dengue tetravalent vaccine (live, attenuated) 
SC 
 
 
2. METHOD OF ADMINISTRATION 
 
 
3. EXPIRY DATE 
 
EXP {MM/YYYY} 
 
 
4. BATCH NUMBER 
 
Lot  
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
5 Doses 
5D 
 
 
6. OTHER 
 
 



 48 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
 
Dengvaxia - Solvent in vial (2.5 mL) 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Solvent for reconstitution of Dengvaxia 
NaCl (0.9%) 
 
 
2. METHOD OF ADMINISTRATION 
 
 
3. EXPIRY DATE 
 
EXP {MM/YYYY} 
 
 
4. BATCH NUMBER  
 
Lot  
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
5 Doses - 2.5 mL 
5D 
 
 
6. OTHER 
 
 
  



 49 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

B. PACKAGE LEAFLET  



 50 

Package Leaflet: Information for the User  
 

Dengvaxia, powder and solvent for suspension for injection in pre-filled syringe 
dengue tetravalent vaccine (live, attenuated) 

 

This medicine is subject to additional monitoring. This will allow quick identification of new 
safety information. You can help by reporting any side effects you may get. See the end of section 4 
for how to report side effects. 
 
Read all of this leaflet carefully before you or your child is vaccinated because it contains 
important information for you. 
• Keep this leaflet. You may need to read it again. 
• If you have any further questions, ask your doctor, pharmacist or nurse. 
• This vaccine has been prescribed for you or your child only. Do not pass it on to others. 
• If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes 

any possible side effects not listed in this leaflet. See section 4. 
 
What is in this leaflet 
 
1. What Dengvaxia is and what it is used for 
2. What you need to know before you or your child use Dengvaxia 
3. How to use Dengvaxia 
4. Possible side effects  
5. How to store Dengvaxia 
6. Contents of the pack and other information 
 
 
1. What Dengvaxia is and what it is used for  
 
Dengvaxia is a vaccine. It is used to help protect you or your child against "dengue disease" caused by 
dengue virus serotypes 1, 2, 3 and 4. It contains versions of these 4 varieties of the virus that have 
been weakened so that they cannot cause the disease. 
 
Dengvaxia is given to adults, young people and children (from 9 to 45 years of age) with prior dengue 
virus infection and who live in endemic areas (also see sections 2 and 3).  
Endemic areas are areas where the disease has been continuously present among the people who live 
there and where outbreaks or epidemics have occurred.  
 
Dengvaxia should be used according to official recommendations. 
 
How the vaccine works 
Dengvaxia stimulates the body’s natural defences (immune system), to produces antibodies that will 
help protect against the viruses that cause dengue disease if the body is exposed to them in the future. 
 
What is dengue and dengue disease? 
Dengue is a viral infection which spreads through the bite of an infected Aedes mosquito. The virus 
from an infected person can spread to other people through mosquito bites for about 4 to 5 days 
(maximum 12 days) after the first symptoms appear. Dengue is not transmitted directly from person-
to-person. 
 
Dengue disease results in symptoms including fever, headache, pain behind the eyes, muscle and joint 
pain, feeling sick (nausea), being sick (vomiting), swollen glands or skin rash. Symptoms usually last 
for 2 to 7 days. You can also have dengue but show no symptoms (called "asymptomatic"). 
 



 51 

Occasionally dengue can be severe enough for you to have to go to hospital and in rare cases it can 
cause death. Severe dengue can give you a high fever and any of the following: severe abdominal 
(belly) pain, persistent sickness (vomiting), rapid breathing, severe bleeding, bleeding in the stomach, 
bleeding gums, feeling tired, feeling restless, coma, having fits (seizures) and organ failure. 
 
 
2. What you need to know before you or your child use Dengvaxia  
 
To make sure that Dengvaxia is suitable for you or your child, it is important to tell your doctor, 
pharmacist or nurse if any of the points below apply to you or your child. If there is anything you do 
not understand, ask your doctor, pharmacist or nurse to explain. 
 
Do not use Dengvaxia if you or your child 
• Know you are allergic to the active substances or any of the other ingredients of Dengvaxia 

(listed in section 6). 
• had an allergic reaction after using Dengvaxia before. Signs of an allergic reaction may include 

an itchy rash, shortness of breath and swelling of the face and tongue. 
• have a weak immune system (the body's natural defences). This may be due to a genetic defect 

or HIV infection. 
• are taking a medicine that affects the immune system (such as high-dose corticosteroids or 

chemotherapy). Your doctor will not use Dengvaxia until 4 weeks after you stop treatment. 
• are pregnant or breast-feeding. 
 
Warnings and precautions 
If you or your child have never been infected by dengue virus before vaccination, you may have an 
increased risk of a more serious dengue illness that may lead to hospitalisation if you are later bitten 
by a dengue-infected mosquito.  
Before the administration of Dengvaxia, your doctor, pharmacist or nurse will check if you or your 
child have ever been infected by dengue virus, and will tell you if a serotesting has to be performed. 
 
Tell your doctor, pharmacist or nurse before using Dengvaxia if you or your child have: 
• a mild to high fever or acute disease. You will not get Dengvaxia until you or your child have 

recovered. 
• ever had any health problems when given a vaccine. Your doctor will carefully consider the 

risks and benefits of vaccination. 
• ever fainted from an injection. Fainting, and sometime falling, can occur (mostly in young 

people) following, or even before, any injection with a needle.  
• had any allergic reaction to latex. The tip cap of the pre-filled syringe contains a natural rubber 

latex which may cause an allergic reaction. 
 
Travellers 
Vaccination is not recommended if you live in area where dengue infections do not regularly occur 
and if you plan to travel to an area where dengue infections regularly occur. 
 
Outbreaks 
Dengvaxia should not be used in the context of dengue outbreak (sudden occurrence of disease) in 
non-endemic regions. 
 
Important information about the protection provided 
As with any vaccines, Dengvaxia may not protect everybody who has been vaccinated. You must 
continue to protect yourself against mosquito bites even after vaccination.  
 
After vaccination, you should consult a doctor if you or your child believe you might have a dengue 
infection, and develop any of the following symptoms: high fever, severe abdominal pain, persistent 
vomiting, rapid breathing, bleeding gums, tiredness, restlessness and blood in vomit. 
 



 52 

Additional protection precautions 
You should take precautions to prevent mosquito bites. This includes using insect repellents, wearing 
protective clothing, and using mosquito nets. 
 
Younger children 
Children less than 9 years of age must not receive the vaccine. 
 
Other medicines and Dengvaxia 
Tell your doctor or pharmacist if you or your child are using, have recently used or might use any 
other vaccines or medicines. 
 
In particular, tell your doctor or pharmacist if you are taking any of the following: 
• medicines that affect your body’s natural defences (immune system) such as high-dose 

corticosteroids or chemotherapy. In this case, your doctor will not use Dengvaxia until 4 weeks 
after you stop treatment. This is because Dengvaxia might not work as well. 

• medicines called “immunoglobulins” or blood products containing immuno globulins, such as 
blood or plasma. In this case, your doctor will not use Dengvaxia until 6 weeks, and preferably 
not for 3 months after you stop treatment. This is because Dengvaxia might not work as well.  

 
Pregnancy and breast-feeding 
Do not use Dengvaxia if you or your daughter are pregnant or breast-feeding. If you or your daughter:  
• are of child-bearing age, you must use an effective method of contraception to avoid pregnancy 

for at least one month after each Dengvaxia dose. 
• think you or your daughter may be pregnant or are planning to have a baby, ask your doctor, 

pharmacist or nurse for advice before using Dengvaxia. 
 
Driving and using machines 
Dengvaxia has minor influence on the ability to drive and use machines. 
 
Dengvaxia contains phenylalanine, sodium and sorbitol 
Dengvaxia contains 41 micrograms of phenylalanine in each 0.5 ml dose. Phenylalanine may be 
harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up 
because the body cannot remove it properly. 
 
Dengvaxia contains less than 1mmol of sodium (23 mg) per 0.5 ml dose, that is to say essentially 
“sodium-free”. 
 
Dengvaxia contains 9.38 milligrams of sorbitol in each 0.5 ml dose. 
 
3. How to use Dengvaxia  
 
Dengvaxia is given by your doctor or nurse as an injection under the skin (subcutaneous injection) in 
the upper arm. It must not be injected into a blood vessel. 
 
You or your child will receive 3 injections of 0.5 mL – one every 6 months. 
• The first injection will be given at the chosen or scheduled date. 
• The second injection, 6 months after the first injection. 
• The third injection, 6 months after the second injection. 
 
Dengvaxia should be used according to official recommendations. 
Previous dengue infection has to be assessed by laboratory confirmed history of dengue or through 
serotesting according to official recommendations. 
 
Instructions for preparing the vaccine intended for medical and healthcare professionals are 
included at the end of the leaflet. 
 
If you or your child miss an injection of Dengvaxia 



 53 

• If you or your child miss a scheduled injection, your doctor will decide when to give the missed 
injection. It is important that you or your child follow the instructions of your doctor, 
pharmacist or nurse regarding follow-up injection.  

• If you forget or are not able to go back at the schedule time, ask your doctor, pharmacist or 
nurse for advice. 

If you have any further questions on the use of this product, ask your doctor, pharmacist or nurse. 
 
 
4. Possible side effects  
 
Like all medicines, Dengvaxia can cause side effects, although not everybody gets them. 
 
Serious allergic (anaphylactic) reactions 
If any of these symptoms occur after leaving the place where you or your child received an injection, 
contact a doctor immediately: 
• difficulty breathing 
• blueness of the tongue or lips 
• a rash 
• swelling of the face or throat  
• low blood pressure causing dizziness or fainting 
• sudden and serious feeling of illness or unease with drop in blood pressure causing dizziness 

and loss of consciousness, rapid heartbeat linked with breathing difficulty. 
 
These signs or symptoms (anaphylactic reactions) usually develop soon after the injection is given and 
while you or your child are still in the clinic or doctor’s surgery. They can also happen very rarely 
after receiving any vaccine (may affect up to 1 in 10 000 people). 
 
Other serious reactions  
For some people who have not been infected by dengue before vaccination, there may be an increased 
risk of getting a more serious dengue illness requiring hospitalisation if they become bitten by a 
dengue-infected mosquito later. This increased risk may mainly begin during the third year following 
the first injection. 
 
Other side effects 
The following side effects occurred during studies in children, young people and adults. Most of the 
side effects occurred within 3 days of having the injection of Dengvaxia. 
 
Very common: (may affect more than 1 in 10 people) 
• headache 
• muscle pain (myalgia) 
• generally feeling unwell (malaise)  
• weakness (asthenia) 
• injection site pain 
• fever. 
 
Common: (may affect up to 1 in 10 people) 
• injection site reactions: redness (erythema), bruising (haematoma), swelling, and itching 

(pruritus). 
 
Uncommon: (may affect up to 1 in 100 people) 
• infections of the nose or throat (upper respiratory tract) 
• feeling dizzy 
• sore throat (oropharyngeal pain) 
• cough 
• feeling sick (nausea) 
• rash (skin eruption) 



 54 

• neck pain 
• hardening of skin at the injection site (injection site induration). 
 
Very rare: (may affect up to 1 in 10 000 people) 
• allergic reactions. 
 
Additional side effects in adults:  
Uncommon: (may affect up to 1 in 100 people) 
• pain or swelling of the nose or throat (nasopharyngitis) 
• swollen glands (lymphadenopathy) 
• dry mouth 
• skin eruption over the whole body (rash generalized) 
• joint pain (arthralgia) 
• injection site warmth 
• chills 
• fatigue. 
 
Additional side effects in children and adolescents (from 9 to and including 17 years of age): 
Uncommon: (may affect up to 1 in 100 people) 
• itchy rash (urticaria). 

 
Rare: (may affect up to 1 in 1000 people) 
• runny nose (rhinorrhea). 
 
Reporting of side effects  
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.  
 
 
5. How to store Dengvaxia  
 
Keep Dengvaxia out of the sight and reach of children. 
 
Do not use Dengvaxia after the expiry date that is stated on the carton after EXP. The expiry date 
refers to the last day of that month. 
 
Store in a refrigerator (2°C to 8°C). 
 
Do not freeze. 
 
Keep the vaccine in the outer carton in order to protect it from light. 
 
After mixing (reconstitution) with the solvent provided, the product should be used immediately. 
 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. 
 
 
6. Contents of the pack and other information  
 
What Dengvaxia contains 
• After reconstitution, one dose (0.5 mL) contains 4.5 - 6.0 log10 CCID50* of each serotype of the 

chimeric yellow fever dengue virus** (1, 2, 3 and 4) (live, attenuated). 
* CCID50: 50% Cell Culture Infectious Dose. 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 55 

** Produced in Vero cells by recombinant DNA technology. This product contains genetically 
modified organisms (GMOs). 

 
• The other ingredients are: essential amino acids including Phenylalanine, non-essential amino 

acids, Arginine hydrochloride, Sucrose, Trehalose dihydrate, Sorbitol (E420), trometamol, urea, 
sodium chloride, water for injections and hydrochloric acid and sodium hydroxide for pH 
adjustment. 

 
What Dengvaxia looks like and contents of the pack 
Dengvaxia is a powder and solvent for suspension for injection. Dengvaxia is provided as a powder in 
a single-dose vial and a solvent in single-dose pre-filled syringe (0.5 mL) with 2 separate needles or 
with no needle. The powder and the solvent must be mixed together before use. 
 
Dengvaxia is available in packs of 1 or 10. Not all pack sizes may be marketed. 
 
The powder is a white, homogenous, freeze-dried powder with possible retraction at the base (ring-
shaped cake possible). 
 
The solvent (0.4% sodium chloride solution) is a clear and colourless solution. 
 
After reconstitution with the solvent provided, Dengvaxia is a clear, colourless liquid with the possible 
presence of white to translucent particles. 
 
Marketing Authorisation Holder: 
Sanofi Pasteur 
14 Espace Henry Vallée 
69007 Lyon 
France 
 
Manufacturer: 
SANOFI PASTEUR 
Parc Industriel d'Incarville 
27100 Val de Reuil 
France 
 
Or 
 
SANOFI PASTEUR NVL 
31-33 Quai Armand Barbès 
69250 Neuville-sur-Saône 
France 
 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
 



 56 

België/ Belgique /Belgien 
Sanofi Belgium 
tel.: +32 2 710.54.00 

Lietuva 
Sanofi – Aventis Lietuva, UAB 
Tel.: +370 5 2755224  

България 
Sanofi Bulgaria EOOD  
Teл.: +359 2 970 53 00 

Luxembourg/Luxemburg 
Sanofi Belgium 
tel.: +32 2 710.54.00 

Česká republika 
Sanofi Pasteur 
divize. vakcín sanofi-aventis, s.r.o. 
Tel: +420 233 086 111 

Magyarország 
sanofi-aventis zrt 
Tel.: +36 1 505 0055 
 

Danmark 
Sanofi A/S 
Tel: +45 4516 7000 

Malta 
Sanofi S.p.A. 
Tel: +39 02 39394983 

Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel.: 0800 54 54 010 
Tel. aus dem Ausland: +49 69 305 21 130 

Nederland 
sanofi-aventis Netherlands B.V. 
Tel: +31 20 245 4000 

Eesti 
Sanofi-Aventis Estonia OÜ 
Tel.: +372 627 3488 

Norge 
Sanofi-aventis Norge AS 
Tel: + 47 67 10 71 00 

Ελλάδα 
Sanofi-aventis AEBE 
Τηλ.+30 210 900 16 00 

Österreich 
Sanofi-Aventis GmbH 
Tel: +43 (1) 80185-0. 

España 
sanofi-aventis, S.A.  
Tel: +34 93 485 94 00 

Polska 
Sanofi Pasteur Sp. z o.o. 
Tel.: +48 22 280 05 00 

France 
Sanofi Pasteur Europe 
Tél: 0800 42 43 46 
Appel depuis l’étranger : +33 1 57 63 67 97  

Portugal 
Sanofi – Produtos Farmacêuticos, Lda. 
Tel: + 351 21 35 89 400 
 

Hrvatska 
sanofi-aventis Croatia d.o.o 
Tel.: +385 1 6003 400 

România 
Sanofi Romania SRL 
Tel.: +40(21) 317 31 36 

Ireland 
sanofi-aventis Ireland T/A SANOFI 
Tel: + 353 (0) 1 4035 600 

Slovenija 
sanofi-aventis d.o.o. 
Tel.: +386 1 560 48 00 

Ísland 
Vistor 
Tel : +354 535 7000 

Slovenská republika 
sanofi-aventis Pharma Slovakia s.r.o. 
divízia vakcín Sanofi Pasteur 
Tel.: +421 2 33 100 100 

Italia 
Sanofi S.p.A. 
Tel: 800536389  
Tel dall'estero: +39 02 39394983 

Suomi/Finland 
Sanofi Oy 
Tel: +358 (0) 201 200 300 
 

Κύπρος 
sanofi-aventis Cyprus Ltd. 
Τηλ.: +357 – 22 871600 

Sverige 
Sanofi AB 
Tel: +46 8-634 50 00 

Latvija 
Sanofi Aventis Latvia SIA Vakcīnu nodaļa 
Tel.: +371 67332451 

United Kingdom 
Sanofi 
Tel: +44 845 372 7101 

 
This leaflet was last revised in [{MM/YYYY}]. 
 
Other sources of information 
 
Detailed information on this medicine is available on the European Medicines Agency web site: 



 57 

http://www.ema.europa.eu. 
 
Path to more information on dengue and vaccination by scanning the QR code included on the outer 
carton with a smartphone. The same information is also available on the following URL: 
http://qr.sanofi.com/dengvaxia 
----------------------------------------------------------------------------------------------------------------------- 
 
The following information is intended for healthcare professionals only: 
• As with all injectable vaccines, appropriate medical treatment and supervision must always be 

readily available in the event of an anaphylactic reaction following the administration of 
Dengvaxia. 

• Dengvaxia must not be mixed with other medicinal products in the same syringe. 
• Dengvaxia must not be administered by intravascular injection under any circumstances. 
• Immunisation should be carried out by subcutaneous (SC) injection preferably in the upper arm 

in the region of the deltoid. 
• Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic 

response to injection with a needle. Procedures should be in place to prevent injury from falling 
and to manage syncopal reactions. 

 
Reconstitution and handling of single-dose presentation  
 
Dengvaxia must be reconstituted prior to administration. 
 
Dengvaxia is reconstituted by transferring all of the solvent (0.4% sodium chloride solution) provided 
in the blue-labeled pre-filled syringe into the vial of freeze-dried powder with a yellowish green 
flip-off cap.  

1. Attach a sterile needle to the pre-filled syringe for the transfer of the solvent. 
2. Transfer the entire content of the pre-filled syringe into the vial containing the powder. 
3. Swirl gently until the powder is completely dissolved. 

 
The suspension should be visually inspected prior to administration. After reconstitution, Dengvaxia is 
a clear, colourless liquid with the possible presence of white to translucent particles (of endogenous 
nature). 
 
After complete dissolution, a 0.5 mL dose of the reconstituted suspension is withdrawn into the same 
syringe. For injection, the syringe should be fitted with a new sterile needle. 
 
Contact with disinfectants is to be avoided since they may inactivate the vaccine viruses. 
 
After reconstitution with the solvent provided, Dengvaxia must be used immediately. 
 
Any unused product or waste material should be disposed of in accordance with local regulations.  
  

http://www.ema.europa.eu/
http://qr.sanofi.com/dengvaxia


 58 

Package Leaflet: Information for the User  
 

Dengvaxia, powder and solvent for suspension for injection in multidose containers 
dengue tetravalent vaccine (live, attenuated) 

 

This medicine is subject to additional monitoring. This will allow quick identification of new 
safety information. You can help by reporting any side effects you may get. See the end of section 4 
for how to report side effects. 
 
Read all of this leaflet carefully before you or your child is vaccinated because it contains 
important information for you. 
• Keep this leaflet. You may need to read it again. 
• If you have any further questions, ask your doctor, pharmacist or nurse. 
• This vaccine has been prescribed for you or your child only. Do not pass it on to others. 
• If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes 

any possible side effects not listed in this leaflet. See section 4. 
 
What is in this leaflet 
 
1. What Dengvaxia is and what it is used for 
2. What you need to know before you or your child use Dengvaxia 
3. How to use Dengvaxia 
4. Possible side effects  
5. How to store Dengvaxia 
6. Contents of the pack and other information 
 
 
1. What Dengvaxia is and what it is used for  
 
Dengvaxia is a vaccine. It is used to help protect you or your child against "dengue disease" caused by 
dengue virus serotypes 1, 2, 3 and 4. It contains versions of these 4 varieties of the virus that have 
been weakened so that they cannot cause the disease. 
 
Dengvaxia is given to adults, young people and children (from 9 to 45 years of age) with prior dengue 
virus infection and who live in endemic areas (also see sections 2 and 3).  
Endemic areas are areas where the disease has been continuously present among the people who live 
there and where outbreaks or epidemics have occurred.  
 
Dengvaxia should be used according to official recommendations. 
 
How the vaccine works 
Dengvaxia stimulates the body’s natural defences (immune system), to produces antibodies that will 
help protect against the viruses that cause dengue disease if the body is exposed to them in the future. 
 
What is dengue and dengue disease? 
Dengue is a viral infection which spreads through the bite of an infected Aedes mosquito. The virus 
from an infected person can spread to other people through mosquito bites for about 4 to 5 days 
(maximum 12 days) after the first symptoms appear. Dengue is not transmitted directly from person-
to-person. 
 
Dengue disease results in symptoms including fever, headache, pain behind the eyes, muscle and joint 
pain, feeling sick (nausea), being sick (vomiting), swollen glands or skin rash. Symptoms usually last 
for 2 to 7 days. You can also have dengue but show no symptoms (called "asymptomatic"). 
 



 59 

Occasionally dengue can be severe enough for you to have to go to hospital and in rare cases it can 
cause death. Severe dengue can give you a high fever and any of the following: severe abdominal 
(belly) pain, persistent sickness (vomiting), rapid breathing, severe bleeding, bleeding in the stomach, 
bleeding gums, feeling tired, feeling restless, coma, having fits (seizures) and organ failure. 
 
 
2. What you need to know before you or your child use Dengvaxia  
 
To make sure that Dengvaxia is suitable for you or your child, it is important to tell your doctor, 
pharmacist or nurse if any of the points below apply to you or your child. If there is anything you do 
not understand, ask your doctor, pharmacist or nurse to explain. 
 
Do not use Dengvaxia if you or your child 
• Know you are allergic to the active substances or any of the other ingredients of Dengvaxia 

(listed in section 6). 
• had an allergic reaction after using Dengvaxia before. Signs of an allergic reaction may include 

an itchy rash, shortness of breath and swelling of the face and tongue. 
• have a weak immune system (the body's natural defences). This may be due to a genetic defect 

or HIV infection. 
• are taking a medicine that affects the immune system (such as high-dose corticosteroids or 

chemotherapy). Your doctor will not use Dengvaxia until 4 weeks after you stop treatment. 
• are pregnant or breast-feeding. 
 
Warnings and precautions 
If you or your child have never been infected by dengue virus before vaccination, you may have an 
increased risk of a more serious dengue illness that may lead to hospitalisation if you are later bitten 
by a dengue-infected mosquito.  
Before the administration of Dengvaxia, your doctor, pharmacist or nurse will check if you or your 
child have ever been infected by dengue virus, and will tell you if a serotesting has to be performed. 
 
Tell your doctor, pharmacist or nurse before using Dengvaxia if you or your child have: 
• a mild to high fever or acute disease. You will not get Dengvaxia until you or your child have 

recovered. 
• ever had any health problems when given a vaccine. Your doctor will carefully consider the 

risks and benefits of vaccination. 
• ever fainted from an injection. Fainting, and sometime falling, can occur (mostly in young 

people) following, or even before, any injection with a needle. 
 
Travellers 
Vaccination is not recommended if you live in area where dengue infections do not regularly occur 
and if you plan to travel to an area where dengue infections regularly occur. 
 
Outbreaks 
Dengvaxia should not be used in the context of dengue outbreak (sudden occurrence of disease) in 
non-endemic regions. 
 
Important information about the protection provided 
As with any vaccines, Dengvaxia may not protect everybody who has been vaccinated. You must 
continue to protect yourself against mosquito bites even after vaccination.  
 
After vaccination, you should consult a doctor if you or your child believe you might have a dengue 
infection, and develop any of the following symptoms: high fever, severe abdominal pain, persistent 
vomiting, rapid breathing, bleeding gums, tiredness, restlessness and blood in vomit. 
 



 60 

Additional protection precautions 
You should take precautions to prevent mosquito bites. This includes using insect repellents, wearing 
protective clothing, and using mosquito nets. 
 
Younger children 
Children less than 9 years of age must not receive the vaccine. 
 
Other medicines and Dengvaxia 
Tell your doctor or pharmacist if you or your child are using, have recently used or might use any 
other vaccines or medicines. 
 
In particular, tell your doctor or pharmacist if you are taking any of the following: 
• medicines that affect your body’s natural defences (immune system) such as high-dose 

corticosteroids or chemotherapy. In this case, your doctor will not use Dengvaxia until 4 weeks 
after you stop treatment. This is because Dengvaxia might not work as well. 

• medicines called “immunoglobulins” or blood products containing immuno globulins, such as 
blood or plasma. In this case, your doctor will not use Dengvaxia until 6 weeks, and preferably 
not for 3 months after you stop treatment. This is because Dengvaxia might not work as well.  

 
Pregnancy and breast-feeding 
Do not use Dengvaxia if you or your daughter are pregnant or breast-feeding. If you or your daughter:  
• are of child-bearing age, you must use an effective method of contraception to avoid pregnancy 

for at least one month after each Dengvaxia dose. 
• think you or your daughter may be pregnant or are planning to have a baby, ask your doctor, 

pharmacist or nurse for advice before using Dengvaxia. 
 
Driving and using machines 
Dengvaxia has minor influence on the ability to drive and use machines. 
 
Dengvaxia contains phenylalanine, sodium and sorbitol 
Dengvaxia contains 8 micrograms of phenylalanine in each 0.5 ml dose. Phenylalanine may be 
harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up 
because the body cannot remove it properly. 
 
Dengvaxia contains less than 1mmol of sodium (23 mg) per 0.5 ml dose, that is to say essentially 
“sodium-free”. 
 
Dengvaxia contains 1.76 milligrams of sorbitol in each 0.5 ml dose. 
 
3. How to use Dengvaxia  
 
Dengvaxia is given by your doctor or nurse as an injection under the skin (subcutaneous injection) in 
the upper arm. It must not be injected into a blood vessel. 
 
You or your child will receive 3 injections of 0.5 mL – one every 6 months. 
• The first injection will be given at the chosen or scheduled date. 
• The second injection, 6 months after the first injection. 
• The third injection, 6 months after the second injection. 
 
Dengvaxia should be used according to official recommendations. 
Previous dengue infection has to be assessed by laboratory confirmed history of dengue or through 
serotesting according to official recommendations. 
 
Instructions for preparing the vaccine intended for medical and healthcare professionals are 
included at the end of the leaflet. 
 
If you or your child miss an injection of Dengvaxia 



 61 

 
• If you or your child miss a scheduled injection, your doctor will decide when to give the missed 

injection. It is important that you or your child follow the instructions of your doctor, 
pharmacist or nurse regarding follow-up injection.  

• If you forget or are not able to go back at the schedule time, ask your doctor, pharmacist or 
nurse for advice. 

If you have any further questions on the use of this product, ask your doctor, pharmacist or nurse. 
 
 
4. Possible side effects  
 
Like all medicines, Dengvaxia can cause side effects, although not everybody gets them. 
 
Serious allergic (anaphylactic) reactions 
If any of these symptoms occur after leaving the place where you or your child received an injection, 
contact a doctor immediately: 
• difficulty breathing 
• blueness of the tongue or lips 
• a rash 
• swelling of the face or throat  
• low blood pressure causing dizziness or fainting 
• sudden and serious feeling of illness or unease with drop in blood pressure causing dizziness 

and loss of consciousness, rapid heartbeat linked with breathing difficulty. 
 
These signs or symptoms (anaphylactic reactions) usually develop soon after the injection is given and 
while you or your child are still in the clinic or doctor’s surgery. They can also happen very rarely 
after receiving any vaccine (may affect up to 1 in 10 000 people). 
 
Other serious reactions  
For some people who have not been infected by dengue before vaccination, there may be an increased 
risk of getting a more serious dengue illness requiring hospitalisation if they become bitten by a 
dengue-infected mosquito later. This increased risk may mainly begin during the third year following 
the first injection. 
 
Other side effects 
The following side effects occurred during studies in children, young people and adults. Most of the 
side effects occurred within 3 days of having the injection of Dengvaxia. 
 
Very common: (may affect more than 1 in 10 people) 
• headache 
• muscle pain (myalgia) 
• generally feeling unwell (malaise)  
• weakness (asthenia) 
• injection site pain 
• fever. 
 
Common: (may affect up to 1 in 10 people) 
• injection site reactions: redness (erythema), bruising (haematoma), swelling, and itching 

(pruritus). 
 
Uncommon: (may affect up to 1 in 100 people) 
• infections of the nose or throat (upper respiratory tract) 
• feeling dizzy 
• sore throat (oropharyngeal pain) 
• cough 
• feeling sick (nausea) 



 62 

• rash (skin eruption) 
• neck pain 
• hardening of skin at the injection site (injection site induration). 
 
Very rare: (may affect up to 1 in 10 000 people) 
• allergic reactions. 
 
Additional side effects in adults:  
Uncommon: (may affect up to 1 in 100 people) 
• pain or swelling of the nose or throat (nasopharyngitis) 
• swollen glands (lymphadenopathy) 
• dry mouth 
• skin eruption over the whole body (rash generalized) 
• joint pain (arthralgia) 
• injection site warmth 
• chills 
• fatigue. 
 
Additional side effects in children and adolescents (from 9 to and including 17 years of age): 
Uncommon: (may affect up to 1 in 100 people) 
• itchy rash (urticaria). 

 
Rare: (may affect up to 1 in 1000 people) 
• runny nose (rhinorrhea). 
 
Reporting of side effects  
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.  
 
 
5. How to store Dengvaxia  
 
Keep Dengvaxia out of the sight and reach of children. 
 
Do not use Dengvaxia after the expiry date that is stated on the carton after EXP. The expiry date 
refers to the last day of that month. 
 
Store in a refrigerator (2°C to 8°C). 
 
Do not freeze. 
 
Keep the vaccine in the outer carton in order to protect it from light. 
 
After mixing (reconstitution) with the solvent provided, the product must be used within 6 hours if 
stored between 2°C and 8°C (i.e., in a refrigerator) and protected from light. 
 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. 
 
 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 63 

6. Contents of the pack and other information  
 
What Dengvaxia contains 
• After reconstitution, one dose (0.5 mL) contains 4.5 - 6.0 log10 CCID50* of each serotype of the 

chimeric yellow fever dengue virus** (1, 2, 3 and 4) (live, attenuated). 
* CCID50: 50% Cell Culture Infectious Dose. 
** Produced in Vero cells by recombinant DNA technology. This product contains genetically 
modified organisms (GMOs). 

 
• The other ingredients are: essential amino acids including Phenylalanine, non-essential amino 

acids, Arginine hydrochloride, Sucrose, Trehalose dihydrate, Sorbitol (E420), trometamol, urea, 
sodium chloride, water for injections and hydrochloric acid and sodium hydroxide for pH 
adjustment. 

 
What Dengvaxia looks like and contents of the pack 
Dengvaxia is a powder and solvent for suspension for injection. Dengvaxia is provided as a powder in 
a 5-dose vial and a solvent in a 5-dose vial (2.5 mL). The powder and the solvent must be mixed 
together before use. 
 
Dengvaxia is available in packs of 5 (vaccine and solvent vials provided in the same box).  
 
The powder is a white, homogenous, freeze-dried powder with possible retraction at the base (ring-
shaped cake possible). 
 
The solvent (0.9% sodium chloride solution) is a limpid, colourless solution. 
 
After reconstitution with the solvent provided, Dengvaxia is a clear, colourless liquid with the possible 
presence of white to translucent particles. 
 
Marketing Authorisation Holder: 
Sanofi Pasteur  
14 Espace Henry Vallée  
69007 Lyon  
France 
 
Manufacturer: 
SANOFI PASTEUR  
Parc Industriel d'Incarville 
27100 Val de Reuil 
France 
 
Or 
 
SANOFI PASTEUR NVL  
31-33 Quai Armand Barbès  
69250 Neuville-sur-Saône  
France 
 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
 



 64 

België/ Belgique /Belgien 
Sanofi Belgium 
tel.: +32 2 710.54.00 

Lietuva 
Sanofi – Aventis Lietuva, UAB 
Tel.: +370 5 2755224  

България 
Sanofi Bulgaria EOOD  
Teл.: +359 2 970 53 00 

Luxembourg/Luxemburg 
Sanofi Belgium 
tel.: +32 2 710.54.00 

Česká republika 
Sanofi Pasteur 
divize. vakcín sanofi-aventis, s.r.o. 
Tel: +420 233 086 111 

Magyarország 
sanofi-aventis zrt 
Tel.: +36 1 505 0055 
 

Danmark 
Sanofi A/S 
Tel: +45 4516 7000 

Malta 
 Sanofi S.p.A. 
Tel: +39 02 39394983 

Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel.: 0800 54 54 010 
Tel. aus dem Ausland: +49 69 305 21 130 

Nederland 
sanofi-aventis Netherlands B.V. 
Tel: +31 20 245 4000 

Eesti 
Sanofi-Aventis Estonia OÜ 
Tel.: +372 627 3488 

Norge 
Sanofi-aventis Norge AS 
Tel: + 47 67 10 71 00 

Ελλάδα 
Sanofi-aventis AEBE 
Τηλ.+30 210 900 16 00 

Österreich 
Sanofi-Aventis GmbH 
Tel: +43 (1) 80185-0. 

España 
sanofi-aventis, S.A.  
Tel: +34 93 485 94 00 

Polska 
Sanofi Pasteur Sp. z o.o. 
Tel.: +48 22 280 05 00 

France 
Sanofi Pasteur Europe 
Tél: 0800 42 43 46 
Appel depuis l’étranger : +33 1 57 63 67 97  

Portugal 
Sanofi – Produtos Farmacêuticos, Lda. 
Tel: + 351 21 35 89 400 
 

Hrvatska 
sanofi-aventis Croatia d.o.o 
Tel.: +385 1 6003 400 

România 
Sanofi Romania SRL 
Tel.: +40(21) 317 31 36 

Ireland 
sanofi-aventis Ireland T/A SANOFI 
Tel: + 353 (0) 1 4035 600 

Slovenija 
sanofi-aventis d.o.o. 
Tel.: +386 1 560 48 00 

Ísland 
Vistor 
Tel : +354 535 7000 

Slovenská republika 
sanofi-aventis Pharma Slovakia s.r.o. 
divízia vakcín Sanofi Pasteur 
Tel.: +421 2 33 100 100 

Italia 
Sanofi S.p.A. 
Tel: 800536389  
Tel dall'estero: +39 02 39394983 

Suomi/Finland 
Sanofi Oy 
Tel: +358 (0) 201 200 300 

Κύπρος 
sanofi-aventis Cyprus Ltd. 
Τηλ.: +357 – 22 871600 

Sverige 
Sanofi AB 
Tel: +46 8-634 50 00 

Latvija 
Sanofi Aventis Latvia SIA Vakcīnu nodaļa 
Tel.: +371 67332451 

United Kingdom 
Sanofi 
Tel: +44 845 372 7101 

 
This leaflet was last revised in [{MM/YYYY}]. 
 
Other sources of information 
 
Detailed information on this medicine is available on the European Medicines Agency web site: 



 65 

http://www.ema.europa.eu. 
 
Path to more information on dengue and vaccination by scanning the QR code included on the outer 
carton with a smartphone. The same information is also available on the following URL: 
http://qr.sanofi.com/dengvaxia 
----------------------------------------------------------------------------------------------------------------------- 
 
The following information is intended for healthcare professionals only: 
• As with all injectable vaccines, appropriate medical treatment and supervision must always be 

readily available in the event of an anaphylactic reaction following the administration of 
Dengvaxia. 

• Dengvaxia must not be mixed with other medicinal products in the same syringe. 
• Dengvaxia must not be administered by intravascular injection under any circumstances.  
• Immunisation should be carried out by subcutaneous (SC) injection preferably in the upper arm 

in the region of the deltoid. 
• Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic 

response to injection with a needle. Procedures should be in place to prevent injury from falling 
and to manage syncopal reactions. 

 
Reconstitution and handling of multidose presentation 
 
Dengvaxia must be reconstituted prior to administration. 
 
Dengvaxia is reconstituted by transferring all of the solvent (0.9% sodium chloride solution) provided 
in the 5-dose vial with a dark gray flip-off cap into the 5-dose vial of freeze-dried powder with a 
medium brown flip-off cap, using a sterile syringe and needle.  

1. Use a sterile syringe and needle for the transfer of the solvent. 
2. Transfer the entire content of the solvent vial (with a dark gray flip-off cap) into the vial 
containing the powder (medium brown flip-off cap). 
3. Swirl gently until the powder is dissolved. 

 
The suspension should be visually inspected prior to administration. After reconstitution, Dengvaxia is 
a clear, colourless liquid with the possible presence of white to translucent particles (of endogenous 
nature). 
 
After complete dissolution, a 0.5 mL dose of the reconstituted suspension is withdrawn into a sterile 
syringe. A new sterile syringe and needle should be used for withdrawal of each of the 5 doses. The 
recommended size of the needle to be used is 23G or 25G. 
 
Before each injection, the reconstituted suspension should be gently swirled once again. 
 
Contact with disinfectants is to be avoided since they may inactivate the vaccine viruses. 
 
After reconstitution with the solvent provided, Dengvaxia must be used within 6 hours. 
 
Partially used multidose vials must be kept between 2°C and 8°C (i.e., in a refrigerator) and protected 
from light. 
 
Any remaining vaccine doses should be discarded at the end of the immunization session or within 6 
hours after reconstitution, whichever comes first. 
 
A partially used multidose vial must be discarded immediately if: 
• Sterile dose withdrawal has not been fully observed. 
• A new sterile syringe and needle were not used for reconstitution or withdrawal of each of the 

previous doses. 
• There is any suspicion that the partially used vial has been contaminated. 
• There is visible evidence of contamination, such as a change in appearance. 

http://www.ema.europa.eu/
http://qr.sanofi.com/dengvaxia


 66 

 
Any unused product or waste material should be disposed of in accordance with local regulations. 
 


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET